

The immune contexture in cancer prognosis and treatment

Nature Reviews Clinical Oncology

14, 717-734

DOI: [10.1038/nrclinonc.2017.101](https://doi.org/10.1038/nrclinonc.2017.101)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Cancer Immunotherapy Getting Brainy: Visualizing the Distinctive CNS Metastatic Niche to Illuminate Therapeutic Resistance. <i>Drug Resistance Updates</i> , 2017, 33-35, 23-35.	6.5	16
2	A Blueprint to Advance Colorectal Cancer Immunotherapies. <i>Cancer Immunology Research</i> , 2017, 5, 942-949.	1.6	63
3	Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications. <i>Oncolmunology</i> , 2017, 6, e1371896.	2.1	36
4	Trial watch: Immune checkpoint blockers for cancer therapy. <i>Oncolmunology</i> , 2017, 6, e1373237.	2.1	62
5	Impact of the Tumor Microenvironment on Tumor-Infiltrating Lymphocytes: Focus on Breast Cancer. <i>Breast Cancer: Basic and Clinical Research</i> , 2017, 11, 117822341773156.	0.6	36
6	Patterns of calcium signaling: A link between chronic emotions and cancer. <i>Journal of Integrative Neuroscience</i> , 2017, 16, S43-S63.	0.8	3
7	New agents for the management of resistant metastatic breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1815-1831.	0.9	5
8	Phenotypic and Functional Properties of Tumor-Infiltrating Regulatory T Cells. <i>Mediators of Inflammation</i> , 2017, 2017, 1-9.	1.4	33
9	Mesenchymal traits at the convergence of tumor-intrinsic and -extrinsic mechanisms of resistance to immune checkpoint blockers. <i>Emerging Topics in Life Sciences</i> , 2017, 1, 471-486.	1.1	5
10	Immune Checkpoint Inhibition in Hodgkin Lymphoma. <i>HemaSphere</i> , 2018, 2, e20.	1.2	15
11	The autophagic network and cancer. <i>Nature Cell Biology</i> , 2018, 20, 243-251.	4.6	233
12	The inflammation “ cancer connection. <i>FEBS Journal</i> , 2018, 285, 638-640.	2.2	63
13	Heating it up: Oncolytic viruses make tumors “hot” and suitable for checkpoint blockade immunotherapies. <i>Oncolmunology</i> , 2018, 7, e1442169.	2.1	85
14	Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models. <i>Oncolmunology</i> , 2018, 7, e1445457.	2.1	13
15	Genomics and emerging biomarkers for immunotherapy of colorectal cancer. <i>Seminars in Cancer Biology</i> , 2018, 52, 189-197.	4.3	112
16	TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas. <i>Oncolmunology</i> , 2018, 7, e1442999.	2.1	53
17	T Cell Dysfunction in Cancer. <i>Cancer Cell</i> , 2018, 33, 547-562.	7.7	787
18	The impact of the intestinal microbiota in therapeutic responses against cancer. <i>Comptes Rendus - Biologies</i> , 2018, 341, 284-289.	0.1	65

#	ARTICLE	IF	CITATIONS
19	The gut microbiota influences anticancer immunosurveillance and general health. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 382-396.	12.5	389
20	Androgen receptor moonlighting in the prostate cancer microenvironment. <i>Endocrine-Related Cancer</i> , 2018, 25, R331-R349.	1.6	18
21	Immuno-oncology-101: overview of major concepts and translational perspectives. <i>Seminars in Cancer Biology</i> , 2018, 52, 1-11.	4.3	39
22	The Role of Immune Escape and Immune Cell Infiltration in Breast Cancer. <i>Breast Care</i> , 2018, 13, 16-21.	0.8	135
23	Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here. <i>Cancer</i> , 2018, 124, 2086-2103.	2.0	141
24	Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma. <i>Cancer Research</i> , 2018, 78, 1308-1320.	0.4	238
25	Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers. <i>Seminars in Cancer Biology</i> , 2018, 52, 125-134.	4.3	51
26	The Human Tumor Microenvironment. , 2018, , 5-21.		2
27	Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcome. <i>Onc Immunology</i> , 2018, 7, e1423184.	2.1	38
28	High-Dimensional Profiling of Tumor-Specific Immune Responses: Asking T Cells about What They "See" in Cancer. <i>Cancer Immunology Research</i> , 2018, 6, 2-9.	1.6	15
29	Multitasking discoidin domain receptors are involved in several and specific hallmarks of cancer. <i>Cell Adhesion and Migration</i> , 2018, 12, 1-15.	1.1	35
30	Immune-based identification of cancer patients at high risk of progression. <i>Current Opinion in Immunology</i> , 2018, 51, 97-102.	2.4	29
31	Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs. <i>Cancer Treatment Reviews</i> , 2018, 65, 78-86.	3.4	32
32	Epigenetics of malignant melanoma. <i>Seminars in Cancer Biology</i> , 2018, 51, 80-88.	4.3	95
33	Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer. <i>Onc Immunology</i> , 2018, 7, e1378844.	2.1	179
34	Physical Activity and Colorectal Cancer Prognosis According to Tumor-Infiltrating T Cells. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky058.	1.4	10
35	Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2995-3006.	0.8	223
36	Proton beam therapy and immunotherapy: an emerging partnership for immune activation in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, 180-188.	1.3	28

#	ARTICLE	IF	CITATIONS
37	Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature. , 2018, 6, 126.		40
38	Tumour heterogeneity and metastasis at single-cell resolution. Nature Cell Biology, 2018, 20, 1349-1360.	4.6	423
39	Targeting Chemokines and Chemokine Receptors in Melanoma and Other Cancers. Frontiers in Immunology, 2018, 9, 2480.	2.2	57
40	Aging, inflammation and cancer. Seminars in Immunology, 2018, 40, 74-82.	2.7	103
41	A Computational Approach Identifies Immunogenic Features of Prognosis in Human Cancers. Frontiers in Immunology, 2018, 9, 3017.	2.2	8
42	Data-Driven Discovery of Immune Contexture Biomarkers. Frontiers in Oncology, 2018, 8, 627.	1.3	29
43	One Health, Fermented Foods, and Gut Microbiota. Foods, 2018, 7, 195.	1.9	101
44	Antigen Specificity and Clinical Significance of IgG and IgA Autoantibodies Produced in situ by Tumor-Infiltrating B Cells in Breast Cancer. Frontiers in Immunology, 2018, 9, 2660.	2.2	65
45	Development of PARP and Immune-Checkpoint Inhibitor Combinations. Cancer Research, 2018, 78, 6717-6725.	0.4	155
46	Functional Heterogeneity of CD4+ Tumor-Infiltrating Lymphocytes With a Resident Memory Phenotype in NSCLC. Frontiers in Immunology, 2018, 9, 2654.	2.2	85
47	Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients. , 2018, 6, 139.		131
48	Endogenous Galectin-1 in T Lymphocytes Regulates Anti-prostate Cancer Immunity. Frontiers in Immunology, 2018, 9, 2190.	2.2	23
49	The role of protein disulphide isomerase AGR2 in the tumour niche. Biology of the Cell, 2018, 110, 271-282.	0.7	24
50	Multi-Omics Profiling of the Tumor Microenvironment: Paving the Way to Precision Immuno-Oncology. Frontiers in Oncology, 2018, 8, 430.	1.3	57
51	Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nature Reviews Clinical Oncology, 2018, 15, 748-762.	12.5	304
52	Role of Hypoxic Stress in Regulating Tumor Immunogenicity, Resistance and Plasticity. International Journal of Molecular Sciences, 2018, 19, 3044.	1.8	64
54	Il-38 Restricts Skin Inflammation and Anti-Tumor Immunity by Limiting Il-17 Production from T Cells. SSRN Electronic Journal, 2018, , .	0.4	1
55	Potent immunosuppressive effects of the oncometabolite <i>R</i> -2-hydroxyglutarate. Oncolmmunology, 2018, 7, e1528815.	2.1	16

#	ARTICLE	IF	CITATIONS
56	Magnetic resonance imaging and molecular features associated with tumor-infiltrating lymphocytes in breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 101.	2.2	44
57	Cancer-associated malnutrition. <i>European Journal of Clinical Nutrition</i> , 2018, 72, 1255-1259.	1.3	116
58	Resident memory T cells, critical components in tumor immunology. , 2018, 6, 87.		193
59	Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer. <i>Lung Cancer</i> , 2018, 125, 86-92.	0.9	63
60	The hallmarks of successful anticancer immunotherapy. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	419
61	<i>Fusobacterium nucleatum</i> in Colorectal Cancer Relates to Immune Response Differentially by Tumor Microsatellite Instability Status. <i>Cancer Immunology Research</i> , 2018, 6, 1327-1336.	1.6	127
62	Immediate and substantial evolution of T-cell repertoire in peripheral blood and tumor microenvironment of patients with esophageal squamous cell carcinoma treated with preoperative chemotherapy. <i>Carcinogenesis</i> , 2018, 39, 1389-1398.	1.3	13
63	Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models. <i>Oncolmmunology</i> , 2018, 7, e1501137.	2.1	120
64	Vitamin D status after colorectal cancer diagnosis and patient survival according to immune response to tumour. <i>European Journal of Cancer</i> , 2018, 103, 98-107.	1.3	21
65	Quantitative Analyses of the Tumor Microenvironment Composition and Orientation in the Era of Precision Medicine. <i>Frontiers in Oncology</i> , 2018, 8, 390.	1.3	46
66	High neutrophil to lymphocyte ratio and decreased CD69⁺NK cells represent a phenotype of high risk in early-stage breast cancer patients. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 2901-2910.	1.0	13
67	The Paradoxical Role of NKG2D in Cancer Immunity. <i>Frontiers in Immunology</i> , 2018, 9, 1808.	2.2	47
68	mPGES-1 and ALOX5/-15 in tumor-associated macrophages. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 317-334.	2.7	31
69	Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways. <i>World Journal of Urology</i> , 2018, 36, 1727-1740.	1.2	75
70	Temporal changes in immune cell composition and cytokines in response to chemoradiation in rectal cancer. <i>Scientific Reports</i> , 2018, 8, 7565.	1.6	14
71	Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC. <i>Anticancer Research</i> , 2018, 38, 3789-3796.	0.5	64
72	Impact of chemotactic factors and receptors on the cancer immune infiltrate: a bioinformatics study revealing homogeneity and heterogeneity among patient cohorts. <i>Oncolmmunology</i> , 2018, 7, e1484980.	2.1	24
73	Oxygenated lipid signaling in tumor-associated macrophagesâ€”focus on colon cancer. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 289-315.	2.7	10

#	ARTICLE	IF	CITATIONS
74	Immune cell profiling in the age of immune checkpoint inhibitors: implications for biomarker discovery and understanding of resistance mechanisms. <i>Mammalian Genome</i> , 2018, 29, 866-878.	1.0	10
75	Immuno-Oncology: Emerging Targets and Combination Therapies. <i>Frontiers in Oncology</i> , 2018, 8, 315.	1.3	244
76	Prognostic Significance of Tumor-Infiltrating B Cells and Plasma Cells in Human Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 6125-6135.	3.2	287
77	Type I Interferon-Independent Dendritic Cell Priming and Antitumor T Cell Activation Induced by a <i>Mycoplasma fermentans</i> Lipopeptide. <i>Frontiers in Immunology</i> , 2018, 9, 496.	2.2	16
78	Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion. <i>Frontiers in Immunology</i> , 2018, 9, 847.	2.2	812
79	The Prognostic Value of Immune Factors in the Tumor Microenvironment of Penile Squamous Cell Carcinoma. <i>Frontiers in Immunology</i> , 2018, 9, 1253.	2.2	61
80	Next Generation Immunotherapy for Pancreatic Cancer: DNA Vaccination is Seeking New Combo Partners. <i>Cancers</i> , 2018, 10, 51.	1.7	21
81	The Peripheral and Intratumoral Immune Cell Landscape in Cancer Patients: A Proxy for Tumor Biology and a Tool for Outcome Prediction. <i>Biomedicines</i> , 2018, 6, 25.	1.4	19
82	Traceable Bioinspired Nanoparticle for the Treatment of Metastatic Breast Cancer via NIRa€Triggered Intracellular Delivery of Methylene Blue and Cisplatin. <i>Advanced Materials</i> , 2018, 30, e1802378.	11.1	73
83	Pan-cancer deconvolution of tumour composition using DNA methylation. <i>Nature Communications</i> , 2018, 9, 3220.	5.8	205
84	Notch Signaling in the Tumor Microenvironment. <i>Cancer Cell</i> , 2018, 34, 536-548.	7.7	434
85	Cancer-Related Inflammation in Tumor Progression. , 2018, , .		0
86	PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab. <i>Oncolmmunology</i> , 2018, 7, e1460298.	2.1	14
87	Cancer immunotherapy: broadening the scope of targetable tumours. <i>Open Biology</i> , 2018, 8, .	1.5	162
88	TCR repertoire intratumor heterogeneity of CD4⁺ and CD8⁺ T cells in centers and margins of localized lung adenocarcinomas. <i>International Journal of Cancer</i> , 2019, 144, 818-827.	2.3	31
89	Contribution of annexin A1 to anticancer immunosurveillance. <i>Oncolmmunology</i> , 2019, 8, e1647760.	2.1	27
90	Immune Cytolytic Activity Is Associated With Genetic and Clinical Properties of Glioma. <i>Frontiers in Immunology</i> , 2019, 10, 1756.	2.2	35
91	Sphingosine-1-Phosphate and Macrophage Biologyâ€”How the Sphinx Tames the Big Eater. <i>Frontiers in Immunology</i> , 2019, 10, 1706.	2.2	80

#	ARTICLE	IF	CITATIONS
92	The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3934.	1.8	69
93	The Construction and Comprehensive Analysis of ceRNA Networks and Tumor-Infiltrating Immune Cells in Bone Metastatic Melanoma. <i>Frontiers in Genetics</i> , 2019, 10, 828.	1.1	26
94	Macrophages induce CD47 upregulation via IL-6 and correlate with poor survival in hepatocellular carcinoma patients. <i>Oncolmmunology</i> , 2019, 8, e1652540.	2.1	55
95	Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 364.	3.5	63
96	The Remarkable Plasticity of Macrophages: A Chance to Fight Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 1563.	2.2	77
97	Photoacoustic imaging as a tool to probe the tumour microenvironment. <i>DMM Disease Models and Mechanisms</i> , 2019, 12, .	1.2	57
98	Mucosal-Associated Invariant T Cells Display Diminished Effector Capacity in Oesophageal Adenocarcinoma. <i>Frontiers in Immunology</i> , 2019, 10, 1580.	2.2	45
99	An immune infiltration signature to predict the overall survival of patients with colon cancer. <i>IUBMB Life</i> , 2019, 71, 1760-1770.	1.5	67
100	Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy. <i>Lancet Oncology</i> , The, 2019, 20, e452-e463.	5.1	150
101	Distinct prognostic value of circulating anti-telomerase CD4+ Th1 immunity and exhausted PD-1+/TIM-3+ T cells in lung cancer. <i>British Journal of Cancer</i> , 2019, 121, 405-416.	2.9	63
102	Prognostic and predictive role of tumour-associated macrophages in HER2 positive breast cancer. <i>Scientific Reports</i> , 2019, 9, 10961.	1.6	63
103	Macrophages and Metabolism in the Tumor Microenvironment. <i>Cell Metabolism</i> , 2019, 30, 36-50.	7.2	933
104	Brainwashed by extracellular vesicles: the role of extracellular vesicles in primary and metastatic brain tumour microenvironment. <i>Journal of Extracellular Vesicles</i> , 2019, 8, 1627164.	5.5	37
105	The prognostic significance of peritumoral tertiary lymphoid structures in breast cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1733-1745.	2.0	72
106	Imaging of T-cells and their responses during anti-cancer immunotherapy. <i>Theranostics</i> , 2019, 9, 7924-7947.	4.6	77
107	Tumor-associated macrophages expressing galectin-9 identify immunoevasive subtype muscle-invasive bladder cancer with poor prognosis but favorable adjuvant chemotherapeutic response. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 2067-2080.	2.0	34
108	Context-dependent roles of complement in cancer. <i>Nature Reviews Cancer</i> , 2019, 19, 698-715.	12.8	217
110	The Microenvironment of Pituitary Tumors—Biological and Therapeutic Implications. <i>Cancers</i> , 2019, 11, 1605.	1.7	44

#	ARTICLE	IF	CITATIONS
111	IL27R β Deficiency Alters Endothelial Cell Function and Subverts Tumor Angiogenesis in Mammary Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 1022.	1.3	6
112	Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story. <i>Cancers</i> , 2019, 11, 1525.	1.7	28
113	Stereotactic Ablative Radiation Therapy for Pulmonary Recurrence-Based Oligometastatic Non-Small Cell Lung Cancer: Survival and Prognostic Value of Regulatory T Cells. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 1055-1064.	0.4	15
114	Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies. <i>Genes and Diseases</i> , 2019, 6, 232-246.	1.5	44
115	Immune Heterogeneity Between Primary Tumors and Corresponding Metastatic Lesions and Response to Platinum Therapy in Primary Ovarian Cancer. <i>Cancers</i> , 2019, 11, 1250.	1.7	18
116	Proteolytic chemokine cleavage as a regulator of lymphocytic infiltration in solid tumors. <i>Cancer and Metastasis Reviews</i> , 2019, 38, 417-430.	2.7	27
117	Clinical Significance of Tumor-Infiltrating T Cells and Programed Death Ligand-1 in Patients with Pancreatic Cancer. <i>Cancer Investigation</i> , 2019, 37, 463-477.	0.6	6
118	The multifaceted immune regulation of bladder cancer. <i>Nature Reviews Urology</i> , 2019, 16, 613-630.	1.9	123
119	Prognostic value of transcriptomic determination of tumour-infiltrating lymphocytes in localised breast cancer. <i>European Journal of Cancer</i> , 2019, 120, 97-106.	1.3	10
120	TGF β 2 blocks IFN γ release and tumor rejection in spontaneous mammary tumors. <i>Nature Communications</i> , 2019, 10, 4131.	5.8	41
121	Immunometabolic Checkpoints of Treg Dynamics: Adaptation to Microenvironmental Opportunities and Challenges. <i>Frontiers in Immunology</i> , 2019, 10, 1889.	2.2	56
122	Next-generation computational tools for interrogating cancer immunity. <i>Nature Reviews Genetics</i> , 2019, 20, 724-746.	7.7	131
123	Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity. <i>OncImmunology</i> , 2019, 8, e1656502.	2.1	45
124	Advances in Molecular Mechanisms and Immunotherapy Involving the Immune Cell-Promoted Epithelial-to-Mesenchymal Transition in Lung Cancer. <i>Journal of Oncology</i> , 2019, 2019, 1-11.	0.6	19
125	Dendritic Cell Vaccination in Metastatic Melanoma Turns "Non-T Cell Inflamed" into "T-Cell Inflamed" Tumors. <i>Frontiers in Immunology</i> , 2019, 10, 2353.	2.2	22
126	Cysteine Cathepsins in Tumor-Associated Immune Cells. <i>Frontiers in Immunology</i> , 2019, 10, 2037.	2.2	90
127	The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy. <i>Journal of Clinical Medicine</i> , 2019, 8, 1534.	1.0	41
128	STAT3 and STAT5 Targeting for Simultaneous Management of Melanoma and Autoimmune Diseases. <i>Cancers</i> , 2019, 11, 1448.	1.7	20

#	ARTICLE	IF	CITATIONS
129	<p>The correlation of BER protein, IRF3 with CD8+ T cell and their prognostic significance in upper tract urothelial carcinoma</p>. OncoTargets and Therapy, 2019, Volume 12, 7725-7735.	1.0	16
130	Non-nuclear AR Signaling in Prostate Cancer. <i>Frontiers in Chemistry</i> , 2019, 7, 651.	1.8	13
131	Sourcing the immune system to induce immunogenic cell death in Kras-colorectal cancer cells. <i>British Journal of Cancer</i> , 2019, 121, 768-775.	2.9	2
132	Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy. <i>Nature Nanotechnology</i> , 2019, 14, 269-278.	15.6	406
133	Preoperative circulating platelet, neutrophil, and lymphocyte counts predict survival in oral cancer. <i>Oral Diseases</i> , 2019, 25, 1057-1066.	1.5	21
134	Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo. <i>Journal of Visualized Experiments</i> , 2019, , .	0.2	14
135	A multi-institutional study of bladder-preserving therapy for stage II-IV bladder cancer: A Korean Radiation Oncology Group Study (KROG 14-16). <i>PLoS ONE</i> , 2019, 14, e0209998.	1.1	1
136	PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor. <i>Oncolmmunology</i> , 2019, 8, e1541535.	2.1	32
137	Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. <i>Genome Medicine</i> , 2019, 11, 34.	3.6	732
138	Epidemiologic perspectives on immunosuppressed populations and the immunosurveillance and immunocontainment of cancer. <i>American Journal of Transplantation</i> , 2019, 19, 3223-3232.	2.6	31
139	Prognostic value of lymphocyte-to-monocyte ratio in ovarian cancer: a meta-analysis. <i>Journal of Ovarian Research</i> , 2019, 12, 51.	1.3	35
140	Molecular and histological correlations in liver cancer. <i>Journal of Hepatology</i> , 2019, 71, 616-630.	1.8	308
141	Editorial: Immune Outposts on the Inflammatory Frontier: Tertiary Lymphoid Structures as Targets for Immunotherapy of Cancer and Autoimmunity. <i>Frontiers in Immunology</i> , 2019, 10, 993.	2.2	2
142	PD-1 high expression predicts lower local disease control in stage IV M0 nasopharyngeal carcinoma. <i>BMC Cancer</i> , 2019, 19, 503.	1.1	18
143	Activation of RIG-I signaling to increase the pro-inflammatory phenotype of a tumor. <i>Oncotarget</i> , 2019, 10, 2338-2339.	0.8	8
144	Colorectal cancer: A paradigmatic model for cancer immunology and immunotherapy. <i>Molecular Aspects of Medicine</i> , 2019, 69, 123-129.	2.7	30
145	Interferon- β induces cancer cell ferroptosis. <i>Cell Research</i> , 2019, 29, 692-693.	5.7	28
146	Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth. <i>Cancer Immunology Research</i> , 2019, 7, 1091-1105.	1.6	153

#	ARTICLE	IF	CITATIONS
147	Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: An updated meta-analysis of 17079 individuals. <i>Cancer Medicine</i> , 2019, 8, 4135-4148.	1.3	120
148	Prognostic impact of p16 and PD-L1 expression in patients with oropharyngeal squamous cell carcinoma receiving a definitive treatment. <i>Journal of Clinical Pathology</i> , 2019, 72, 542-549.	1.0	26
149	Imaging of Activated T Cells as an Early Predictor of Immune Response to Anti-PD-1 Therapy. <i>Cancer Research</i> , 2019, 79, 3455-3465.	0.4	60
150	Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 857-862.	1.3	52
151	Two cases of intrahepatic cholangiocellular carcinoma with high insertion-deletion ratios that achieved a complete response following chemotherapy combined with PD-1 blockade. , 2019, 7, 125.		32
152	Going to extremes: determinants of extraordinary response and survival in patients with cancer. <i>Nature Reviews Cancer</i> , 2019, 19, 339-348.	12.8	35
153	PD-1/PD-L1 blockade in paediatric cancers: What does the future hold?. <i>Cancer Letters</i> , 2019, 457, 74-85.	3.2	15
154	Tertiary lymphoid structures in the era of cancer immunotherapy. <i>Nature Reviews Cancer</i> , 2019, 19, 307-325.	12.8	879
155	TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 4820-4831.	3.2	71
156	Re-education of macrophages as a therapeutic strategy in cancer. <i>Immunotherapy</i> , 2019, 11, 677-689.	1.0	124
157	Biohybrid Vaccines for Improved Treatment of Aggressive Melanoma with Checkpoint Inhibitor. <i>ACS Nano</i> , 2019, 13, 6477-6490.	7.3	36
158	The Interplay of Autophagy and Tumor Microenvironment in Colorectal Cancer—Ways of Enhancing Immunotherapy Action. <i>Cancers</i> , 2019, 11, 533.	1.7	37
159	Cancer cells induce immune escape via glyocalyx changes controlled by the telomeric protein <sc>TRF</sc>. <i>EMBO Journal</i> , 2019, 38, .	3.5	49
160	Beyond PD-L1 Markers for Lung Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1915.	1.8	61
161	Immune contexture defined by single cell technology for prognosis prediction and immunotherapy guidance in cancer. <i>Cancer Communications</i> , 2019, 39, 1-9.	3.7	40
162	Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs. <i>JAMA Network Open</i> , 2019, 2, e192535.	2.8	842
163	Double Positive CD4+CD8+ T Cells Are Enriched in Urological Cancers and Favor T Helper-2 Polarization. <i>Frontiers in Immunology</i> , 2019, 10, 622.	2.2	55
164	Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity. <i>Immunity</i> , 2019, 50, 778-795.	6.6	639

#	ARTICLE	IF	CITATIONS
165	NK and T cells with a cytotoxic/migratory phenotype accumulate in peritumoral tissue of patients with clear cell renal carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 503-509.	0.8	13
166	The Dark Side of Innate Immunity Fosters Tumor Growth and Offers New Diagnostic. <i>Clinical Cancer Research</i> , 2019, 25, 3199-3201.	3.2	0
167	The role of immune infiltrates as prognostic biomarkers in patients with breast cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1671-1680.	2.0	56
168	Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy. <i>Cancer Letters</i> , 2019, 452, 66-70.	3.2	150
169	Implementation of Mass Cytometry for Immunoprofiling of Patients with Solid Tumors. <i>Journal of Immunology Research</i> , 2019, 2019, 1-10.	0.9	3
170	Automated Analysis of Lymphocytic Infiltration, Tumor Budding, and Their Spatial Relationship Improves Prognostic Accuracy in Colorectal Cancer. <i>Cancer Immunology Research</i> , 2019, 7, 609-620.	1.6	69
171	Tumor Microenvironment Characterization in Gastric Cancer Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures. <i>Cancer Immunology Research</i> , 2019, 7, 737-750.	1.6	691
172	The Immune Subtypes and Landscape of Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 3528-3537.	3.2	136
173	The Tumor Immune Contexture of Prostate Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 603.	2.2	143
174	Host tissue determinants of tumour immunity. <i>Nature Reviews Cancer</i> , 2019, 19, 215-227.	12.8	150
175	Collagen density regulates the activity of tumor-infiltrating T cells. , 2019, 7, 68.		239
176	Drug Repositioning Inferred from E2F1-Coregulator Interactions Studies for the Prevention and Treatment of Metastatic Cancers. <i>Theranostics</i> , 2019, 9, 1490-1509.	4.6	15
177	Innate immunity, inflammation and tumour progression: double-edged swords. <i>Journal of Internal Medicine</i> , 2019, 285, 524-532.	2.7	59
178	Cutting Edge: Polymicrobial Sepsis Has the Capacity to Reinvigorate Tumor-Infiltrating CD8 T Cells and Prolong Host Survival. <i>Journal of Immunology</i> , 2019, 202, 2843-2848.	0.4	20
179	Wnt1 silences chemokine genes in dendritic cells and induces adaptive immune resistance in lung adenocarcinoma. <i>Nature Communications</i> , 2019, 10, 1405.	5.8	68
180	Metabolic enzymes expressed by cancer cells impact the immune infiltrate. <i>OncImmunology</i> , 2019, 8, e1571389.	2.1	15
181	Neoadjuvant Radiochemotherapy Significantly Alters the Phenotype of Plasmacytoid Dendritic Cells and 6-Sulfo LacNAc+ Monocytes in Rectal Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 602.	2.2	8
183	Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy. <i>Advanced Healthcare Materials</i> , 2019, 8, e1801320.	3.9	43

#	ARTICLE	IF	CITATIONS
184	Harnessing the Immune System in HER2+ Disease. , 2019, , 213-230.		0
185	2020 vision or myopia? A personal perspective on the future of cancer imaging and an introduction to the sequels to the "How I Read Series". Cancer Imaging, 2019, 19, 7.	1.2	0
186	Prognostic Value of Macrophage Phenotypes in Resectable Non-Small Cell Lung Cancer Assessed by Multiplex Immunohistochemistry. Neoplasia, 2019, 21, 282-293.	2.3	117
187	Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy. Trends in Cell Biology, 2019, 29, 396-416.	3.6	66
188	Bioinformatics Analysis of Key Genes and Pathways in Colorectal Cancer. Journal of Computational Biology, 2019, 26, 364-375.	0.8	14
189	Cancer Vaccines. , 2019, , .		1
190	Targeting of the Cancer-Associated Fibroblast-T-Cell Axis in Solid Malignancies. Journal of Clinical Medicine, 2019, 8, 1989.	1.0	42
191	Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment. Journal of Hematology and Oncology, 2019, 12, 125.	6.9	116
192	Tumor Characterization in Breast Cancer Identifies Immune-Relevant Gene Signatures Associated With Prognosis. Frontiers in Genetics, 2019, 10, 1119.	1.1	64
193	EuroFlow and its activities: Introduction to the special EuroFlow issue of The Journal of Immunological Methods. Journal of Immunological Methods, 2019, 475, 112704.	0.6	2
194	Biomarker for personalized immunotherapy. Translational Lung Cancer Research, 2019, 8, S308-S317.	1.3	7
195	Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy. Breast Cancer Research, 2019, 21, 142.	2.2	21
196	The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications. Molecular Cancer, 2019, 18, 184.	7.9	54
197	Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma. Journal of Hepatology, 2019, 70, 58-65.	1.8	219
198	Tumor-infiltrating T cells and PD-L1 expression in childhood malignant extracranial germ-cell tumors. OncoImmunology, 2019, 8, e1542245.	2.1	18
199	Systemic autophagy in the therapeutic response to anthracycline-based chemotherapy. OncoImmunology, 2019, 8, e1498285.	2.1	25
200	Rethinking Communication in the Immune System: The Quorum Sensing Concept. Trends in Immunology, 2019, 40, 88-97.	2.9	33
201	High Density of Intratumor CD45RO+ Memory Tumor-Infiltrating Lymphocytes Predicts Favorable Prognosis in Patients With Oral Squamous Cell Carcinoma. Journal of Oral and Maxillofacial Surgery, 2019, 77, 536-545.	0.5	16

#	ARTICLE	IF	CITATIONS
202	Nondestructive, multiplex three-dimensional mapping of immune infiltrates in core needle biopsy. <i>Laboratory Investigation</i> , 2019, 99, 1400-1413.	1.7	18
203	The clinical role of the TME in solid cancer. <i>British Journal of Cancer</i> , 2019, 120, 45-53.	2.9	380
204	Prognosis assessment by pathologist: Is the detection of intratumoural tertiary lymphoid structures a reliable tool?. <i>Journal of Hepatology</i> , 2019, 70, 11-12.	1.8	0
205	Intratumoral IL17-producing cells infiltration correlate with antitumor immune contexture and improved response to adjuvant chemotherapy in gastric cancer. <i>Annals of Oncology</i> , 2019, 30, 266-273.	0.6	48
206	Gold Standard Assessment of Immunogenic Cell Death in Oncological Mouse Models. <i>Methods in Molecular Biology</i> , 2019, 1884, 297-315.	0.4	51
208	Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma. <i>Annals of Oncology</i> , 2019, 30, 57-67.	0.6	167
209	Enhancing tumor T cell infiltration to enable cancer immunotherapy. <i>Immunotherapy</i> , 2019, 11, 201-213.	1.0	108
210	Stromal lymphocyte infiltration is associated with tumour invasion depth but is not prognostic in high-grade T1 bladder cancer. <i>European Journal of Cancer</i> , 2019, 108, 111-119.	1.3	16
211	Hyperspectral cell sociology reveals spatial tumor-immune cell interactions associated with lung cancer recurrence. , 2019, 7, 13.		37
212	Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 463-474.	1.4	16
213	Integration of microbiology, molecular pathology, and epidemiology: a new paradigm to explore the pathogenesis of microbiome-driven neoplasms. <i>Journal of Pathology</i> , 2019, 247, 615-628.	2.1	70
214	Time for radioimmunotherapy: an overview to bring improvements in clinical practice. <i>Clinical and Translational Oncology</i> , 2019, 21, 992-1004.	1.2	13
215	Immune cell constitution in bone marrow microenvironment predicts outcome in adult ALL. <i>Leukemia</i> , 2019, 33, 1570-1582.	3.3	43
216	The intimate relationship between gut microbiota and cancer immunotherapy. <i>Gut Microbes</i> , 2019, 10, 424-428.	4.3	98
217	Smoking and Risk of Colorectal Cancer Sub-Classified by Tumor-Infiltrating T Cells. <i>Journal of the National Cancer Institute</i> , 2019, 111, 42-51.	3.0	30
218	The lung microenvironment: an important regulator of tumour growth and metastasis. <i>Nature Reviews Cancer</i> , 2019, 19, 9-31.	12.8	692
219	Blocking IL-1 β reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 1361-1369.	3.3	302
220	Cancer Immun surveillance by T Cells. <i>International Review of Cell and Molecular Biology</i> , 2019, 342, 149-173.	1.6	45

#	ARTICLE	IF	CITATIONS
221	Regulation of tumor-stroma interactions by the unfolded protein response. <i>FEBS Journal</i> , 2019, 286, 279-296.	2.2	33
222	Harnessing the immune system to fight cancer with Toll-like receptor and RIG-I-like receptor agonists. <i>Pharmacological Research</i> , 2020, 154, 104192.	3.1	45
223	The prognostic effect of immunoscore in patients with clear cell renal cell carcinoma: preliminary results. <i>International Urology and Nephrology</i> , 2020, 52, 21-34.	0.6	14
224	Oncolysis without viruses "inducing systemic anticancer immune responses with local therapies. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 49-64.	12.5	92
225	Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy. <i>Clinical and Translational Oncology</i> , 2020, 22, 603-611.	1.2	36
226	Intrahepatic immune changes after hepatitis c virus eradication by direct-acting antiviral therapy. <i>Liver International</i> , 2020, 40, 74-82.	1.9	14
227	Oncolytic Viruses. <i>Methods in Molecular Biology</i> , 2020, , .	0.4	4
228	Intratumoral IL22-producing cells define immunoevasive subtype muscle-invasive bladder cancer with poor prognosis and superior nivolumab responses. <i>International Journal of Cancer</i> , 2020, 146, 542-552.	2.3	22
229	Therapeutic Targeting of the Colorectal Tumor Stroma. <i>Gastroenterology</i> , 2020, 158, 303-321.	0.6	51
230	Integrating tumor hypoxic stress in novel and more adaptable strategies for cancer immunotherapy. <i>Seminars in Cancer Biology</i> , 2020, 65, 140-154.	4.3	66
231	Tumour immune cell infiltration and survival after platinum-based chemotherapy in high-grade serous ovarian cancer subtypes: A gene expression-based computational study. <i>EBioMedicine</i> , 2020, 51, 102602.	2.7	78
232	CTLA-4 correlates with immune and clinical characteristics of glioma. <i>Cancer Cell International</i> , 2020, 20, 7.	1.8	74
233	Recent progress in supramolecular peptide assemblies as virus mimics for cancer immunotherapy. <i>Biomaterials Science</i> , 2020, 8, 1045-1057.	2.6	20
234	The potential application of PD-1 blockade therapy for early-stage biliary tract cancer. <i>International Immunology</i> , 2020, 32, 273-281.	1.8	10
235	An Engineered Tumor-on-a-Chip Device with Breast Cancer-Immune Cell Interactions for Assessing T-cell Recruitment. <i>Cancer Research</i> , 2020, 80, 263-275.	0.4	89
237	Immunoscore system combining CD8 and PD-1/PD-L1: A novel approach that predicts the clinical outcomes for cervical cancer. <i>International Journal of Biological Markers</i> , 2020, 35, 65-73.	0.7	19
238	Immune checkpoint inhibitors for refractory childhood cancers. <i>Lancet Oncology</i> , The, 2020, 21, 14-15.	5.1	2
239	Personalized Medicine in Practice: Postgenomics from Multiplicity to Immutability. <i>Body and Society</i> , 2020, 26, 26-54.	0.3	8

#	ARTICLE	IF	CITATIONS
240	A minimal modeling framework of radiation and immune system synergy to assist radiotherapy planning. <i>Journal of Theoretical Biology</i> , 2020, 486, 110099.	0.8	4
241	Regulation of tumor growth by leukocyte-specific protein 1 in T cells. , 2020, 8, e001180.		5
242	Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma. <i>Frontiers in Immunology</i> , 2020, 11, 2105.	2.2	164
243	The complexity of neutrophils in health and disease: Focus on cancer. <i>Seminars in Immunology</i> , 2020, 48, 101409.	2.7	31
244	Manipulation of Glucose Availability to Boost Cancer Immunotherapies. <i>Cancers</i> , 2020, 12, 2940.	1.7	15
245	Prognostic and Predictive Value of Tumor-Infiltrating Immune Cells in Urothelial Cancer of the Bladder. <i>Cancers</i> , 2020, 12, 2692.	1.7	29
246	Prognostic significance of tumor-associated macrophages: past, present and future. <i>Seminars in Immunology</i> , 2020, 48, 101408.	2.7	40
247	Metformin changes the immune microenvironment of colorectal cancer in patients with type 2 diabetes mellitus. <i>Cancer Science</i> , 2020, 111, 4012-4020.	1.7	30
248	An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression. <i>Cancer Immunology Research</i> , 2020, 8, 1568-1582.	1.6	23
249	The biologically functional identification of a novel TIM3-binding peptide P26 in vitro and in vivo. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 783-792.	1.1	4
250	Heat Shock Protein 90 Family Isoforms as Prognostic Biomarkers and Their Correlations with Immune Infiltration in Breast Cancer. <i>BioMed Research International</i> , 2020, 2020, 1-15.	0.9	15
251	The murine Microenvironment Cell Population counter method to estimate abundance of tissue-infiltrating immune and stromal cell populations in murine samples using gene expression. <i>Genome Medicine</i> , 2020, 12, 86.	3.6	63
252	An immune landscape based prognostic signature predicts the immune status and immunotherapeutic responses of patients with colorectal cancer. <i>Life Sciences</i> , 2020, 261, 118368.	2.0	8
253	Comprehensive Study of Tumor Immune Microenvironment and Relevant Genes in Hepatocellular Carcinoma Identifies Potential Prognostic Significance. <i>Frontiers in Oncology</i> , 2020, 10, 554165.	1.3	7
254	Breast cancer cell debris diminishes therapeutic efficacy through heme oxygenase-1-mediated inactivation of M1-like tumor-associated macrophages. <i>Neoplasia</i> , 2020, 22, 606-616.	2.3	15
255	The Resistance Mechanisms of Lung Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 568059.	1.3	47
256	Comprehensive analysis of a 14 immune-related gene pair signature to predict the prognosis and immune features of gastric cancer. <i>International Immunopharmacology</i> , 2020, 89, 107074.	1.7	11
257	Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7032.	1.8	20

#	ARTICLE	IF	CITATIONS
258	Dendritic cells in the tumor microenvironment: prognostic and theranostic impact. <i>Seminars in Immunology</i> , 2020, 48, 101410.	2.7	81
259	Neutrophil diversity and plasticity in tumour progression and therapy. <i>Nature Reviews Cancer</i> , 2020, 20, 485-503.	12.8	548
260	Combinatorial Immunotherapies for Metastatic Colorectal Cancer. <i>Cancers</i> , 2020, 12, 1875.	1.7	19
261	Immune-infiltration based signature as a novel prognostic biomarker in gastrointestinal stromal tumour. <i>EBioMedicine</i> , 2020, 57, 102850.	2.7	20
262	<p>Glucometabolic Reprogramming in the Hepatocellular Carcinoma Microenvironment: Cause and Effect</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 5957-5974.	0.9	21
263	Trial watch: STING agonists in cancer therapy. <i>Oncolmmunology</i> , 2020, 9, 1777624.	2.1	148
264	Trial watch: IDO inhibitors in cancer therapy. <i>Oncolmmunology</i> , 2020, 9, 1777625.	2.1	91
265	Inflammation and lymphocyte infiltration are associated with shorter survival in patients with high-grade glioma. <i>Oncolmmunology</i> , 2020, 9, 1779990.	2.1	28
266	Telomerase and CD4 T Cell Immunity in Cancer. <i>Cancers</i> , 2020, 12, 1687.	1.7	20
267	Induction of Immune Response against Metastatic Tumors via Vaccination of Mannan&BAM, TLR Ligands, and Anti&CD40 Antibody (MBTA). <i>Advanced Therapeutics</i> , 2020, 3, 2000044.	1.6	11
268	Antagonistic Inflammatory Phenotypes Dictate Tumor Fate and Response to Immune Checkpoint Blockade. <i>Immunity</i> , 2020, 53, 1215-1229.e8.	6.6	131
269	The Angiopoietin-2 and TIE Pathway as a Therapeutic Target for Enhancing Antiangiogenic Therapy and Immunotherapy in Patients with Advanced Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8689.	1.8	38
270	Immune-related lncRNAs as predictors of survival in breast cancer: a prognostic signature. <i>Journal of Translational Medicine</i> , 2020, 18, 442.	1.8	72
271	Investigation of the prognostic value of CD4 T cell subsets expanded from tumor-infiltrating lymphocytes of colorectal cancer liver metastases. , 2020, 8, e001478.		22
272	Tumor-associated macrophage, angiogenesis and lymphangiogenesis markers predict prognosis of non-small cell lung cancer patients. <i>Journal of Translational Medicine</i> , 2020, 18, 443.	1.8	124
273	Tumor-infiltrating podoplanin ⁺ cells in gastric cancer: clinical outcomes and association with immune contexture. <i>Oncolmmunology</i> , 2020, 9, 1845038.	2.1	7
274	Applications of Single-Cell Omics to Dissect Tumor Microenvironment. <i>Frontiers in Genetics</i> , 2020, 11, 548719.	1.1	18
275	New insights into the interaction of the immune system with non-small cell lung carcinomas. <i>Translational Lung Cancer Research</i> , 2020, 9, 2199-2213.	1.3	11

#	ARTICLE	IF	CITATIONS
276	Nanomedicines modulating tumor immunosuppressive cells to enhance cancer immunotherapy. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 2054-2074.	5.7	65
277	Tumor-infiltrating TNFRSF9 ⁺ CD8 ⁺ T cells define different subsets of clear cell renal cell carcinoma with prognosis and immunotherapeutic response. <i>Oncolmmunology</i> , 2020, 9, 1838141.	2.1	23
278	Mathematical and Computational Oncology. <i>Lecture Notes in Computer Science</i> , 2020, , .	1.0	0
279	Metabolic regulation of prostate cancer heterogeneity and plasticity. <i>Seminars in Cancer Biology</i> , 2022, 82, 94-119.	4.3	20
280	The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy. <i>Cancers</i> , 2020, 12, 3285.	1.7	85
281	Tissue-engineered 3D cancer microenvironment for screening therapeutics. , 2020, , 453-479.		2
282	Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 725-741.	12.5	701
283	Immune Landscape in Tumor Microenvironment: Implications for Biomarker Development and Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5521.	1.8	25
284	Immune Cell Infiltration and Identifying Genes of Prognostic Value in the Papillary Renal Cell Carcinoma Microenvironment by Bioinformatics Analysis. <i>BioMed Research International</i> , 2020, 2020, 1-12.	0.9	8
285	Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade. <i>Frontiers in Immunology</i> , 2020, 11, 1590.	2.2	50
286	Co-delivery of Peptide Neoantigens and Stimulator of Interferon Genes Agonists Enhances Response to Cancer Vaccines. <i>ACS Nano</i> , 2020, 14, 9904-9916.	7.3	97
287	Unraveling the Complexity of the Cancer Microenvironment With Multidimensional Genomic and Cytometric Technologies. <i>Frontiers in Oncology</i> , 2020, 10, 1254.	1.3	45
288	Prognostic Value of Immune Environment Analysis in Small Bowel Adenocarcinomas with Verified Mutational Landscape and Predisposing Conditions. <i>Cancers</i> , 2020, 12, 2018.	1.7	5
289	Identification of Immune-Related Prognostic Genes and LncRNAs Biomarkers Associated With Osteosarcoma Microenvironment. <i>Frontiers in Oncology</i> , 2020, 10, 1109.	1.3	12
290	The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. <i>Nature Reviews Cancer</i> , 2020, 20, 662-680.	12.8	860
291	Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors. <i>Cells</i> , 2020, 9, 1727.	1.8	8
292	Coordinated Cellular Neighborhoods Orchestrate Antitumoral Immunity at the Colorectal Cancer Invasive Front. <i>Cell</i> , 2020, 182, 1341-1359.e19.	13.5	464
293	Bone metastasis is associated with acquisition of mesenchymal phenotype and immune suppression in a model of spontaneous breast cancer metastasis. <i>Scientific Reports</i> , 2020, 10, 13838.	1.6	23

#	ARTICLE	IF	CITATIONS
294	Injectable Reactive Oxygen Species-Responsive SN38 Prodrug Scaffold with Checkpoint Inhibitors for Combined Chemoimmunotherapy. <i>ACS Applied Materials & Interfaces</i> , 2020, 12, 50248-50259.	4.0	33
295	Why is cancer not more common? A changing microenvironment may help to explain why, and suggests strategies for anti-cancer therapy. <i>Open Biology</i> , 2020, 10, 190297.	1.5	4
296	Expression of TAM-R in Human Immune Cells and Unique Regulatory Function of MerTK in IL-10 Production by Tolerogenic DC. <i>Frontiers in Immunology</i> , 2020, 11, 564133.	2.2	22
298	Innate Immune Training of Granulopoiesis Promotes Anti-tumor Activity. <i>Cell</i> , 2020, 183, 771-785.e12.	13.5	277
299	Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker. <i>Cancer Medicine</i> , 2020, 9, 8086-8121.	1.3	95
300	Distinct tumor immune microenvironments in primary and metastatic lesions in gastric cancer patients. <i>Scientific Reports</i> , 2020, 10, 14293.	1.6	18
301	Lack of myeloid cell infiltration as an acquired resistance strategy to immunotherapy. , 2020, 8, e001326.		16
302	Immune infiltrating cells in duodenal cancers. <i>Journal of Translational Medicine</i> , 2020, 18, 340.	1.8	3
303	Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 2: The Role of Novel PET Agents. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1553-1559.	2.8	16
304	Classification of Muscle-Invasive Bladder Cancer Based on Immunogenomic Profiling. <i>Frontiers in Oncology</i> , 2020, 10, 1429.	1.3	16
305	Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor. <i>Cancer Medicine</i> , 2020, 9, 8258-8265.	1.3	9
306	Infiltration by IL22-Producing T Cells Promotes Neutrophil Recruitment and Predicts Favorable Clinical Outcome in Human Colorectal Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 1452-1462.	1.6	15
307	TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals. <i>Frontiers in Immunology</i> , 2020, 11, 1689.	2.2	63
308	Tackling TAMs for Cancer Immunotherapy: It's Nano Time. <i>Trends in Pharmacological Sciences</i> , 2020, 41, 701-714.	4.0	60
309	Microneedles loaded with anti-PD-1 cisplatin nanoparticles for synergistic cancer immuno-chemotherapy. <i>Nanoscale</i> , 2020, 12, 18885-18898.	2.8	67
310	Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook. <i>Molecular Cancer</i> , 2020, 19, 141.	7.9	141
312	Intratumoral TIGIT ⁺ CD8 ⁺ T-cell infiltration determines poor prognosis and immune evasion in patients with muscle-invasive bladder cancer. , 2020, 8, e000978.		81
313	M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer. , 2020, 8, e000979.		60

#	ARTICLE	IF	CITATIONS
314	Sepsis and Cancer: An Interplay of Friends and Foes. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1625-1635.	2.5	39
315	Molecular and Cellular Factors Associated with Racial Disparity in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5936.	1.8	13
316	Combining multiple spatial statistics enhances the description of immune cell localisation within tumours. <i>Scientific Reports</i> , 2020, 10, 18624.	1.6	20
317	CD8+ T-cell lymphocytes infiltration predict clinical outcomes in Wilms's tumor. <i>Tumor Biology</i> , 2020, 42, 101042832097597.	0.8	19
318	Unveiling the immune infiltrate modulation in cancer and response to immunotherapy by MIXTURE: an enhanced deconvolution method. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	11
319	Identification of tumor-associated macrophage subsets that are associated with breast cancer prognosis. <i>Clinical and Translational Medicine</i> , 2020, 10, e239.	1.7	25
320	Combining inhibition of galectin-3 with and before a therapeutic vaccination is critical for the prostate-tumor-free outcome. , 2020, 8, e001535.		11
321	Peritumoral plasmacytoid dendritic cells predict a poor prognosis for intrahepatic cholangiocarcinoma after curative resection. <i>Cancer Cell International</i> , 2020, 20, 582.	1.8	12
322	Immune Cell Infiltrate and Prognosis in Gastric Cancer. <i>Cancers</i> , 2020, 12, 3604.	1.7	11
323	Complement System: Promoter or Suppressor of Cancer Progression?. <i>Antibodies</i> , 2020, 9, 57.	1.2	58
324	Lipid-mediated regulation of the cancer-immune crosstalk. <i>Pharmacological Research</i> , 2020, 161, 105131.	3.1	12
325	Reprogramming the tumour microenvironment by radiotherapy: implications for radiotherapy and immunotherapy combinations. <i>Radiation Oncology</i> , 2020, 15, 254.	1.2	62
326	CD8+ Tumour-Infiltrating Lymphocytes and Tumour Microenvironment Immune Types as Biomarkers for Immunotherapy in Sinonasal Intestinal-Type Adenocarcinoma. <i>Vaccines</i> , 2020, 8, 202.	2.1	15
327	Myeloid PTEN promotes chemotherapy-induced NLRP3-inflammasome activation and antitumour immunity. <i>Nature Cell Biology</i> , 2020, 22, 716-727.	4.6	70
328	B cells and complement at the forefront of chemotherapy. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 393-394.	12.5	9
329	Galectin-9 expression as a poor prognostic factor in patients with renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2041-2051.	2.0	13
330	Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 89.	3.5	157
331	Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint. <i>Frontiers in Immunology</i> , 2020, 11, 951.	2.2	221

#	ARTICLE	IF	CITATIONS
332	Nine-factor-based immunohistochemistry classifier predicts recurrence for early-stage hepatocellular carcinoma after curative resection. <i>British Journal of Cancer</i> , 2020, 123, 92-100.	2.9	10
333	High-dimensional analyses reveal a distinct role of T cell subsets in the immune microenvironment of gastric cancer. <i>Clinical and Translational Immunology</i> , 2020, 9, e1127.	1.7	21
334	Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e89-e106.	1.8	17
335	Perineural Invasion and Postoperative Adjuvant Chemotherapy Efficacy in Patients With Gastric Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 530.	1.3	17
336	Adoptive cellular immunotherapy of tumors <i>via</i> effective CpG delivery to dendritic cells using dendrimer-entrapped gold nanoparticles as a gene vector. <i>Journal of Materials Chemistry B</i> , 2020, 8, 5052-5063.	2.9	30
337	Influence of Innate Immunity on Cancer Cell Stemness. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3352.	1.8	20
338	Long Non-coding RNA LINC02195 as a Regulator of MHC I Molecules and Favorable Prognostic Marker for Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 615.	1.3	31
339	Association between lactate dehydrogenase levels and oncologic outcomes in metastatic prostate cancer: A meta-analysis. <i>Cancer Medicine</i> , 2020, 9, 7341-7351.	1.3	21
340	Memory Lymphocyte Clusters in Genital Immunity: Role of Tissue-Resident Memory T Cells (TRM). <i>Current Topics in Microbiology and Immunology</i> , 2020, 426, 83-117.	0.7	0
341	Programmed death ligand 1/indoleamine 2,3-dioxygenase 1 expression and tumor-infiltrating lymphocyte status in renal cell carcinoma with sarcomatoid changes and rhabdoid features. <i>Human Pathology</i> , 2020, 101, 31-39.	1.1	9
342	Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. <i>Nature Medicine</i> , 2020, 26, 909-918.	15.2	488
343	The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies. <i>Frontiers in Immunology</i> , 2020, 11, 784.	2.2	339
344	A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future. <i>Current Oncology</i> , 2020, 27, 87-97.	0.9	554
345	Prognostic value of the systemic immune-inflammation index in patients with breast cancer: a meta-analysis. <i>Cancer Cell International</i> , 2020, 20, 224.	1.8	53
346	Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors. <i>Cancers</i> , 2020, 12, 1502.	1.7	145
347	Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials. <i>European Journal of Cancer</i> , 2020, 135, 78-88.	1.3	10
348	Combining Qdot Nanotechnology and DNA Nanotechnology for Sensitive Single-Cell Imaging. <i>Advanced Materials</i> , 2020, 32, e1908410.	11.1	24
349	Delineating the evolutionary dynamics of cancer from theory to reality. <i>Nature Cancer</i> , 2020, 1, 580-588.	5.7	29

#	ARTICLE	IF	CITATIONS
350	Large-scale transcriptome profiles reveal robust 20â€signatures metabolic prediction models and novel role of G6PC in clear cell renal cell carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 9012-9027.	1.6	28
351	Lessons from Hippocrates: Time to Change the Cancer Paradigm. <i>International Journal of Chronic Diseases</i> , 2020, 2020, 1-14.	1.9	5
352	Bronchoscopic intratumoural therapies for non-small cell lung cancer. <i>European Respiratory Review</i> , 2020, 29, 200028.	3.0	17
353	Innate Immune Cells and Their Contribution to T-Cell-Based Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4441.	1.8	20
354	A pre-existing coordinated inflammatory microenvironment is associated with complete response of vulvar high-grade squamous intraepithelial lesions to different forms of immunotherapy. <i>International Journal of Cancer</i> , 2020, 147, 2914-2923.	2.3	10
355	Characterization of a Myeloid Activation Signature That Correlates with Survival in Melanoma Patients. <i>Cancers</i> , 2020, 12, 1431.	1.7	1
356	Injectable Therapies for Regional Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 433-444.	0.6	5
357	Stromal LAG-3 ⁺ cells infiltration defines poor prognosis subtype muscle-invasive bladder cancer with immunoevasive contexture. , 2020, 8, e000651.		29
358	Racial differences in CD8+ T cell infiltration in breast tumors from Black and White women. <i>Breast Cancer Research</i> , 2020, 22, 62.	2.2	24
359	Heterogeneity of Glucose Transport in Lung Cancer. <i>Biomolecules</i> , 2020, 10, 868.	1.8	19
360	Pro-tumorigenic functions of macrophages at the primary, invasive and metastatic tumor site. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1673-1697.	2.0	38
361	A four-factor immune risk score signature predicts the clinical outcome of patients with spinal chordoma. <i>Clinical and Translational Medicine</i> , 2020, 10, 224-237.	1.7	22
362	Trial watch: TLR3 agonists in cancer therapy. <i>Oncolmmunology</i> , 2020, 9, 1771143.	2.1	116
363	The Role of Tumor-Associated Myeloid Cells in Modulating Cancer Therapy. <i>Frontiers in Oncology</i> , 2020, 10, 899.	1.3	44
364	Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 364.	2.2	50
365	Difficulties in establishing a causal link between chemical exposures and cancer cannot be overcome by court assessments. <i>Human and Experimental Toxicology</i> , 2020, 39, 1095-1107.	1.1	3
366	DIY: Visualizing the immune landscape of tumors using transcriptome and methylome data. <i>Methods in Enzymology</i> , 2020, 636, 49-76.	0.4	1
367	Custom-designed Small Animal focal iRadiation Jig (SARJ): design, manufacture and dosimetric evaluation. <i>BJR Open</i> , 2020, 2, 20190045.	0.4	1

#	ARTICLE	IF	CITATIONS
368	Single-Cell Approaches to Profile the Response to Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2020, 11, 490.	2.2	38
369	Modulation of tumor microenvironment for immunotherapy: focus on nanomaterial-based strategies. <i>Theranostics</i> , 2020, 10, 3099-3117.	4.6	70
370	Computational methods in tumor immunology. <i>Methods in Enzymology</i> , 2020, 636, 209-259.	0.4	3
371	Identification of immune cells and mRNA associated with prognosis of gastric cancer. <i>BMC Cancer</i> , 2020, 20, 206.	1.1	37
372	Predictive Immune Modeling of Solid Tumors. <i>Journal of Visualized Experiments</i> , 2020, , .	0.2	4
373	Poor clinical outcomes of intratumoral dendritic cell-specific intercellular adhesion molecule 3a-grabbing non-integrin-positive macrophages associated with immune evasion in gastric cancer. <i>European Journal of Cancer</i> , 2020, 128, 27-37.	1.3	28
374	Lymphocyte activation gene-3 (LAG3) mRNA and protein expression on tumour infiltrating lymphocytes (TILs) in oesophageal adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2319-2327.	1.2	25
375	MMP2 as an independent prognostic stratifier in oral cavity cancers. <i>Oncolmmunology</i> , 2020, 9, 1754094.	2.1	15
376	Toward Systems Biomarkers of Response to Immune Checkpoint Blockers. <i>Frontiers in Oncology</i> , 2020, 10, 1027.	1.3	16
377	Biological mechanisms of ectopic lymphoid structure formation and their pathophysiological significance. <i>International Reviews of Immunology</i> , 2021, 40, 255-267.	1.5	4
378	Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer. <i>Cancers</i> , 2020, 12, 1761.	1.7	8
379	Tumor microenvironment characterization in head and neck cancer identifies prognostic and immunotherapeutically relevant gene signatures. <i>Scientific Reports</i> , 2020, 10, 11163.	1.6	28
380	Could Protons and Carbon Ions Be the Silver Bullets Against Pancreatic Cancer?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4767.	1.8	7
381	The relationships between PD-L1 expression, CD8+ TILs and clinico-histomorphological parameters in malignant melanomas. <i>Pathology Research and Practice</i> , 2020, 216, 153071.	1.0	5
382	Integrating the Tumor Microenvironment into Cancer Therapy. <i>Cancers</i> , 2020, 12, 1677.	1.7	24
383	Comprehensive analyses of the heterogeneity and prognostic significance of tumor-infiltrating immune cells in non-small-cell lung cancer: Development and validation of an individualized prognostic model. <i>International Immunopharmacology</i> , 2020, 86, 106744.	1.7	5
384	Metabolism of immune cells in cancer. <i>Nature Reviews Cancer</i> , 2020, 20, 516-531.	12.8	407
385	Multi-dimensional omics characterization in glioblastoma identifies the purity-associated pattern and prognostic gene signatures. <i>Cancer Cell International</i> , 2020, 20, 37.	1.8	14

#	ARTICLE	IF	CITATIONS
386	Overexpression of the human cytomegalovirus UL111A is correlated with favorable survival of patients with gastric cancer and changes T-cell infiltration and suppresses carcinogenesis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 555-568.	1.2	5
387	Bidirectional Crosstalk Between Cancer Stem Cells and Immune Cell Subsets. <i>Frontiers in Immunology</i> , 2020, 11, 140.	2.2	69
388	Monitoring Immune Responses in Neuroblastoma Patients during Therapy. <i>Cancers</i> , 2020, 12, 519.	1.7	30
389	Deconvolution of the immunological contexture of mouse tumors with multiplexed immunohistochemistry. <i>Methods in Enzymology</i> , 2020, 635, 81-93.	0.4	3
390	Progress in triple negative breast carcinoma pathophysiology: Potential therapeutic targets. <i>Pathology Research and Practice</i> , 2020, 216, 152874.	1.0	8
391	Neutrophil traps, anti-myeloperoxidase antibodies and cancer: Are they linked?. <i>Immunology Letters</i> , 2020, 221, 33-38.	1.1	9
392	Systemic immune-inflammation index predicted overall survival and radiosensitivity in advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2020, 16, 103-115.	1.1	14
393	Targeting the Tumor Microenvironment in Colorectal Peritoneal Metastases. <i>Trends in Cancer</i> , 2020, 6, 236-246.	3.8	58
394	Bioinformatics for Cancer Immunotherapy. <i>Methods in Molecular Biology</i> , 2020, , .	0.4	1
395	Very rapid cloning, expression and identifying specificity of T-cell receptors for T-cell engineering. <i>PLoS ONE</i> , 2020, 15, e0228112.	1.1	6
396	The Diagnostic, Prognostic, and Therapeutic Potential of Adaptive Immune Receptor Repertoire Profiling in Cancer. <i>Cancer Research</i> , 2020, 80, 643-654.	0.4	28
397	Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 307-319.	1.8	310
398	The number of FoxP3-positive tumor-infiltrating lymphocytes in patients with synchronous bilateral breast cancer. <i>Breast Cancer</i> , 2020, 27, 586-593.	1.3	5
399	B cells and tertiary lymphoid structures promote immunotherapy response. <i>Nature</i> , 2020, 577, 549-555.	13.7	1,421
400	Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1. <i>Nature Communications</i> , 2020, 11, 437.	5.8	89
401	Clinical importance of the expression of CD4+CD8+ T cells in renal cell carcinoma. <i>International Immunology</i> , 2020, 32, 347-357.	1.8	10
402	Comparison of immune profiles between hepatocellular carcinoma subtypes. <i>Biophysics Reports</i> , 2020, 6, 19-32.	0.2	1
403	ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. <i>European Journal of Cancer</i> , 2020, 127, 52-66.	1.3	52

#	ARTICLE	IF	CITATIONS
404	Tumor Infiltrating Neutrophils Are Enriched in Basal-Type Urothelial Bladder Cancer. <i>Cells</i> , 2020, 9, 291.	1.8	18
405	Clinicopathological and Prognostic Characteristics of CD276 (B7-H3) Expression in Adrenocortical Carcinoma. <i>Disease Markers</i> , 2020, 2020, 1-10.	0.6	12
406	Expression and Prognostic Value of IFIT1 and IFITM3 in Head and Neck Squamous Cell Carcinoma. <i>American Journal of Clinical Pathology</i> , 2020, 153, 618-629.	0.4	15
407	Disparity in Tumor Immune Microenvironment of Breast Cancer and Prognostic Impact: Asian Versus Western Populations. <i>Oncologist</i> , 2020, 25, e16-e23.	1.9	40
408	Tumor Microenvironment Characterization in Glioblastoma Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures. <i>Journal of Molecular Neuroscience</i> , 2020, 70, 738-750.	1.1	6
409	Assessment of lipid load in tumor-infiltrating Tregs by flow cytometry. <i>Methods in Enzymology</i> , 2020, 632, 283-294.	0.4	3
410	High infiltration of mast cells is associated with improved response to adjuvant chemotherapy in gallbladder cancer. <i>Cancer Science</i> , 2020, 111, 817-825.	1.7	8
411	Immunologic impact of chemoradiation in cervical cancer and how immune cell infiltration could lead toward personalized treatment. <i>International Journal of Cancer</i> , 2020, 147, 554-564.	2.3	14
412	Magnetic resonance imaging-based radiomic features for extrapolating infiltration levels of immune cells in lower-grade gliomas. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 913-921.	1.0	19
413	AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells. <i>Journal of Thoracic Oncology</i> , 2020, 15, 973-999.	0.5	66
414	Shaping of the Tumor Microenvironment by Notch Signaling. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1223, 1-16.	0.8	10
415	Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors. <i>Cancers</i> , 2020, 12, 1046.	1.7	47
416	Characterising the prognostic potential of HLA-DR during colorectal cancer development. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1577-1588.	2.0	21
417	Intrinsic Genetic and Transcriptomic Patterns Reflect Tumor Immune Subtypes Facilitating Exploring Possible Combinatory Therapy. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 53.	1.6	1
419	Noninvasive imaging evaluation of tumor immune microenvironment to predict outcomes in gastric cancer. <i>Annals of Oncology</i> , 2020, 31, 760-768.	0.6	101
420	Combining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinoma. <i>British Journal of Cancer</i> , 2020, 122, 1803-1810.	2.9	23
421	Tumour grade significantly correlates with total dysfunction of tumour tissue-infiltrating lymphocytes in renal cell carcinoma. <i>Scientific Reports</i> , 2020, 10, 6220.	1.6	25
422	Clinical impact of combined epigenetic and molecular analysis of pediatric low-grade gliomas. <i>Neuro-Oncology</i> , 2020, 22, 1474-1483.	0.6	39

#	ARTICLE	IF	CITATIONS
423	A purified membrane protein from <i>Akkermansia muciniphila</i> or the pasteurised bacterium blunts colitis associated tumourigenesis by modulation of CD8 ⁺ T cells in mice. <i>Gut</i> , 2020, 69, 1988-1997.	6.1	304
424	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
425	Identification and validation of dichotomous immune subtypes based on intratumoral immune cells infiltration in clear cell renal cell carcinoma patients. , 2020, 8, e000447.		35
426	Immunoscore Predicts Survival in Early-Stage Lung Adenocarcinoma Patients. <i>Frontiers in Oncology</i> , 2020, 10, 691.	1.3	17
427	Identification and validation of poor prognosis immunoevasive subtype of muscle-invasive bladder cancer with tumor-infiltrating podoplanin ⁺ cell abundance. <i>Oncolmmunology</i> , 2020, 9, 1747333.	2.1	13
428	A gene signature for immune subtyping of desert, excluded, and inflamed ovarian tumors. <i>American Journal of Reproductive Immunology</i> , 2020, 84, e13244.	1.2	18
429	Tumor-associated tertiary lymphoid structure predicts postoperative outcomes in patients with primary gastrointestinal stromal tumors. <i>Oncolmmunology</i> , 2020, 9, 1747339.	2.1	30
430	Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?. <i>Frontiers in Pharmacology</i> , 2020, 11, 441.	1.6	48
431	Prevalence of PD-L1 expression is associated with EMAST, density of peritumoral T-cells and recurrence-free survival in operable non-metastatic colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1627-1637.	2.0	16
432	Emerging role of PTEN loss in evasion of the immune response to tumours. <i>British Journal of Cancer</i> , 2020, 122, 1732-1743.	2.9	95
433	Tumor-infiltrating IL-17A ⁺ cells determine favorable prognosis and adjuvant chemotherapeutic response in muscle-invasive bladder cancer. <i>Oncolmmunology</i> , 2020, 9, 1747332.	2.1	6
434	Tumor microenvironment characterization identifies two lung adenocarcinoma subtypes with specific immune and metabolic state. <i>Cancer Science</i> , 2020, 111, 1876-1886.	1.7	16
435	The <i>miR-582</i> / <i>CD1B</i> Axis Is Involved in Regulation of Dendritic Cells and Is Associated with Clinical Outcomes in Advanced Lung Adenocarcinoma. <i>BioMed Research International</i> , 2020, 2020, 1-11.	0.9	8
436	CD226hiCD8 ⁺ T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy. <i>Cancer Immunology Research</i> , 2020, 8, 912-925.	1.6	53
437	High level of EZH2 expression is linked to high density of CD8-positive T-lymphocytes and an aggressive phenotype in renal cell carcinoma. <i>World Journal of Urology</i> , 2021, 39, 481-490.	1.2	11
438	Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 182-191.	3.0	49
439	Oncolytic virus promotes tumor-reactive infiltrating lymphocytes for adoptive cell therapy. <i>Cancer Gene Therapy</i> , 2021, 28, 98-111.	2.2	30
440	Liver prometastatic reaction: Stimulating factors and responsive cancer phenotypes. <i>Seminars in Cancer Biology</i> , 2021, 71, 122-133.	4.3	10

#	ARTICLE	IF	CITATIONS
441	¹⁸F-AraG PET for CD8 Profiling of Tumors and Assessment of Immunomodulation by Chemotherapy. Journal of Nuclear Medicine, 2021, 62, 802-807.	2.3	28
442	Genomic profile and immune contexture in colorectal cancerâ€™relevance for prognosis and immunotherapy. Clinical and Experimental Medicine, 2021, 21, 195-204.	1.9	5
443	Calreticulin and cancer. Cell Research, 2021, 31, 5-16.	5.7	174
444	Anti-PD-1 antibody increases NK cell cytotoxicity towards nasopharyngeal carcinoma cells in the context of chemotherapy-induced upregulation of PD-1 and PD-L1. Cancer Immunology, Immunotherapy, 2021, 70, 323-336.	2.0	25
445	TGFÎ² biology in cancer progression and immunotherapy. Nature Reviews Clinical Oncology, 2021, 18, 9-34.	12.5	420
446	Is hepatitis C direct-acting antiviral therapy a risk factor for the development and recurrence of hepatocellular carcinoma? Narrative literature review and clinical practice recommendations. Annals of Hepatology, 2021, 21, 100225.	0.6	4
447	Stromal categorization in early oral tongue cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 925-932.	1.4	17
448	Baseline immunity and impact of chemotherapy on immune microenvironment in cervical cancer. British Journal of Cancer, 2021, 124, 414-424.	2.9	38
449	An Immune-Related Gene Prognostic Index for Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2021, 27, 330-341.	3.2	148
451	Sendai virus acts as a nano-booster to excite dendritic cells for enhancing the efficacy of CD47-directed immune checkpoint inhibitors against breast carcinoma. Materials Chemistry Frontiers, 2021, 5, 223-237.	3.2	4
452	¹⁸F-AraG PET for CD8 Profiling of Tumors and Assessment of Immunomodulation by Chemotherapy. Journal of Nuclear Medicine, 2021, 62, 802-807.	2.8	15
453	Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells. Cellular and Molecular Immunology, 2021, 18, 112-127.	4.8	159
454	Integrating Machine Learning and Tumor Immune Signature to Predict Oncologic Outcomes in Resected Biliary Tract Cancer. Annals of Surgical Oncology, 2021, 28, 4018-4029.	0.7	11
455	Expression of Human Epidermal Growth Factor Receptor-2 Status and Programmed Cell Death Protein-1 Ligand Is Associated With Prognosis in Gastric Cancer. Frontiers in Oncology, 2020, 10, 580045.	1.3	2
456	Immunosuppression in Gliomas via PD-1/PD-L1 Axis and Adenosine Pathway. Frontiers in Oncology, 2020, 10, 617385.	1.3	18
457	Tumor perfusion enhancement by ultrasound stimulated microbubbles potentiates PD-L1 blockade of MC38 colon cancer in mice. Cancer Letters, 2021, 498, 121-129.	3.2	35
458	Urothelial carcinoma: variant histology, molecular subtyping, and immunophenotyping significant for treatment outcomes. Pathology, 2021, 53, 56-66.	0.3	22
459	Immunotherapy in prostate cancer: new horizon of hurdles and hopes. World Journal of Urology, 2021, 39, 1387-1403.	1.2	17

#	ARTICLE	IF	CITATIONS
460	Tumor-infiltrating lymphocytes in the immunotherapy era. <i>Cellular and Molecular Immunology</i> , 2021, 18, 842-859.	4.8	403
461	An update on the use of immunotherapy in patients with colorectal cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 291-304.	1.4	18
462	Prognostic Value of Tumor Proportion Score in Salivary Gland Carcinoma. <i>Laryngoscope</i> , 2021, 131, E1481-E1488.	1.1	15
463	DREIMT: a drug repositioning database and prioritization tool for immunomodulation. <i>Bioinformatics</i> , 2021, 37, 578-579.	1.8	9
464	The prognostic and predictive role of the neutrophil-to-lymphocyte ratio and the monocyte-to-lymphocyte ratio in early breast cancer, especially in the HER2+ subtype. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 63-72.	1.1	30
465	The prognostic value and potential subtypes of immune activity scores in three major urological cancers. <i>Journal of Cellular Physiology</i> , 2021, 236, 2620-2630.	2.0	3
466	The balance between breast cancer and the immune system: Challenges for prognosis and clinical benefit from immunotherapies. <i>Seminars in Cancer Biology</i> , 2021, 72, 76-89.	4.3	87
467	The Periphery of Salivary Gland Carcinoma Tumors Reveals a PD-L1/PD-1 Biomarker Niche for the Evaluation of Disease Severity and Tumor-Immune System Interplay. <i>Biomedicines</i> , 2021, 9, 97.	1.4	7
468	Antibody-Based Targeting of Interferon-Beta-1a Mutein in HER2-Positive Cancer Enhances Antitumor Effects Through Immune Responses and Direct Cell Killing. <i>Frontiers in Pharmacology</i> , 2020, 11, 608774.	1.6	7
470	Highly Multiplexed Digital Spatial Profiling of the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma Patients. <i>Frontiers in Oncology</i> , 2020, 10, 607349.	1.3	22
471	Predictive Systems Biomarkers of Response to Immune Checkpoint Inhibitors. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
472	Immune cell infiltrates as prognostic biomarkers in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 99-112.	1.3	14
473	Gene co-expression modules integrated with immunoscore predicts survival of non-small cell lung cancer. <i>Cancer Treatment and Research Communications</i> , 2021, 26, 100297.	0.7	4
474	Targeting cancer-promoting inflammation – have anti-inflammatory therapies come of age?. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 261-279.	12.5	171
475	PD-L1+ dendritic cells in the tumor microenvironment correlate with good prognosis and CD8+ T cell infiltration in colon cancer. <i>Cancer Science</i> , 2021, 112, 1173-1183.	1.7	27
476	Unlocking the Power of Exosomes for Crossing Biological Barriers in Drug Delivery. <i>Pharmaceutics</i> , 2021, 13, 122.	2.0	112
477	Inflammation-Driven Breast Tumor Cell Plasticity: Stemness/EMT, Therapy Resistance and Dormancy. <i>Frontiers in Oncology</i> , 2020, 10, 614468.	1.3	38
478	A regulator-based methylation modification patterns characterized by distinct tumor microenvironment immune profiles in colon cancer. <i>Theranostics</i> , 2021, 11, 2201-2217.	4.6	148

#	ARTICLE	IF	CITATIONS
479	Stromal infiltrating mast cells identify immunoevasive subtype high-grade serous ovarian cancer with poor prognosis and inferior immunotherapeutic response. <i>Oncolmmunology</i> , 2021, 10, 1969075.	2.1	18
480	Identification of a Five-Autophagy-Related-lncRNA Signature as a Novel Prognostic Biomarker for Hepatocellular Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 611626.	1.6	32
481	Prognostic value of LRRC4C in Colon and Gastric Cancers correlates with Tumour Microenvironment Immunity. <i>International Journal of Biological Sciences</i> , 2021, 17, 1413-1427.	2.6	6
482	Poor clinical outcomes and immunoevasive contexture in CXCL13+CD8+ T cells enriched gastric cancer patients. <i>Oncolmmunology</i> , 2021, 10, 1915560.	2.1	17
483	Prognostic value of the baseline circulating T cell receptor \hat{I}^2 chain diversity in advanced lung cancer. <i>Oncolmmunology</i> , 2021, 10, 1899609.	2.1	4
484	Identification and Immunocorrelation of Prognosis-Related Genes Associated With Development of Muscle-Invasive Bladder Cancer. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 598599.	1.6	4
485	Development of prognostic signature based on immune-related genes in muscle-invasive bladder cancer: bioinformatics analysis of TCGA database. <i>Aging</i> , 2021, 13, 1859-1871.	1.4	32
486	The Interplay of Exosomes and NK Cells in Cancer Biology. <i>Cancers</i> , 2021, 13, 473.	1.7	30
487	MoNuSAC2020: A Multi-Organ Nuclei Segmentation and Classification Challenge. <i>IEEE Transactions on Medical Imaging</i> , 2021, 40, 3413-3423.	5.4	71
488	Comprehensive analyses reveal TKI-induced remodeling of the tumor immune microenvironment in EGFR/ALK-positive non-small-cell lung cancer. <i>Oncolmmunology</i> , 2021, 10, 1951019.	2.1	33
489	Biological bases of cancer immunotherapy. <i>Expert Reviews in Molecular Medicine</i> , 2021, 23, e3.	1.6	14
490	A genomic instability-derived risk index predicts clinical outcome and immunotherapy response for clear cell renal cell carcinoma. <i>Bioengineered</i> , 2021, 12, 1642-1662.	1.4	6
491	A narrative overview of the prognostic significance of the immune cellular milieu in tumor draining lymph nodes in non-small cell lung cancer. <i>AME Medical Journal</i> , 0, 6, 40-40.	0.4	0
492	The intratumoral CXCR3 chemokine system is predictive of chemotherapy response in human bladder cancer. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	35
493	Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC). <i>Cancers</i> , 2021, 13, 231.	1.7	42
494	Immunophenotypic Differences in Tumor-Infiltrating Lymphocytes and Neovascularization Between Primary Cutaneous Melanoma With and Without Metastasis. <i>American Journal of Dermatopathology</i> , 2021, Publish Ahead of Print, 811-818.	0.3	0
495	Safflower yellow reduces DEN-induced hepatocellular carcinoma by enhancing liver immune infiltration through promotion of collagen degradation and modulation of gut microbiota. <i>Food and Function</i> , 2021, 12, 10632-10643.	2.1	13
496	Characteristics of Infiltrating Immune Cells and a Predictive Immune Model for Cervical Cancer. <i>Journal of Cancer</i> , 2021, 12, 3501-3514.	1.2	11

#	ARTICLE	IF	CITATIONS
497	Phosphorylation of SMAD3 in immune cells predicts survival of patients with early stage non-small cell lung cancer. , 2021, 9, e001469.		12
498	Intratumoral CXCL13 ⁺ CD8 ⁺ T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma. , 2021, 9, e001823.		87
499	CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer. , 2021, 9, e001638.		38
500	Tumor Microenvironment, HLA Class I and APM Expression in HPV-Negative Oral Squamous Cell Carcinoma. Cancers, 2021, 13, 620.	1.7	11
502	Chronic cancer and non-cancer pain and opioid-induced hyperalgesia share common mechanisms: neuroinflammation and central sensitization. Minerva Anestesiologica, 2021, 87, 210-222.	0.6	15
503	Macrophages and Extracellular Matrix in Breast Cancer: Partners in Crime or Protective Allies?. Frontiers in Oncology, 2021, 11, 620773.	1.3	46
504	Impact of cancer evolution on immune surveillance and checkpoint inhibitor response. Seminars in Cancer Biology, 2022, 84, 89-102.	4.3	21
505	Tackling cancer cell dormancy: Insights from immune models, and transplantation. Seminars in Cancer Biology, 2022, 78, 5-16.	4.3	9
506	Integrated Characterization of lncRNA-Immune Interactions in Prostate Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 641891.	1.8	14
507	Understanding relevant immune mechanisms in gastrointestinal oncology. Journal of Oncology Pharmacy Practice, 2021, 27, 107815522199286.	0.5	0
508	A Prognostic Signature Based on Immunogenomic Profiling Offers Guidance for Esophageal Squamous Cell Cancer Treatment. Frontiers in Oncology, 2021, 11, 603634.	1.3	8
509	Establishment and validation of an eight-gene metabolic-related prognostic signature model for lung adenocarcinoma. Aging, 2021, 13, 8688-8705.	1.4	6
510	Crosstalk between Macrophages, T Cells, and Iron Metabolism in Tumor Microenvironment. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-14.	1.9	40
511	Locally advanced gastroesophageal junction cancer with pathological complete response to neoadjuvant therapy: a case report and literature review. Annals of Translational Medicine, 2021, 9, 513-513.	0.7	4
512	Emerging Trends for Radio-Immunotherapy in Rectal Cancer. Cancers, 2021, 13, 1374.	1.7	18
513	The right Timing, right combination, right sequence, and right delivery for Cancer immunotherapy. Journal of Controlled Release, 2021, 331, 321-334.	4.8	35
514	Cytosolic Delivery of Thiolated Mn-GAMP Nanovaccine to Enhance the Antitumor Immune Responses. Small, 2021, 17, e2006970.	5.2	38
515	Biomarkers for Immunotherapy of Oral Squamous Cell Carcinoma: Current Status and Challenges. Frontiers in Oncology, 2021, 11, 616629.	1.3	33

#	ARTICLE	IF	CITATIONS
517	Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort Study. <i>Cancers</i> , 2021, 13, 1324.	1.7	8
518	Histopathological and Immune Prognostic Factors in Colo-Rectal Liver Metastases. <i>Cancers</i> , 2021, 13, 1075.	1.7	5
519	BayICE: A Bayesian hierarchical model for semireference-based deconvolution of bulk transcriptomic data. <i>Annals of Applied Statistics</i> , 2021, 15, .	0.5	3
520	Tertiary lymphoid structure score: a promising approach to refine the TNM staging in resected non-small cell lung cancer. <i>British Journal of Cancer</i> , 2021, 124, 1680-1689.	2.9	37
521	Tumor microenvironment-associated gene C3 can predict the prognosis of colorectal adenocarcinoma: a study based on TCGA. <i>Clinical and Translational Oncology</i> , 2021, 23, 1923-1933.	1.2	5
522	An immune-related seven-lncRNA signature for head and neck squamous cell carcinoma. <i>Cancer Medicine</i> , 2021, 10, 2268-2285.	1.3	14
523	Immunotherapy for pancreatic cancer: chasing the light at the end of the tunnel. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 261-278.	2.1	16
525	Predicting the Level of Tumor-Infiltrating Lymphocytes in Patients With Breast Cancer: Usefulness of Mammographic Radiomics Features. <i>Frontiers in Oncology</i> , 2021, 11, 628577.	1.3	13
526	Comprehensive analysis of immune-related prognostic genes in the tumour microenvironment of hepatocellular carcinoma. <i>BMC Cancer</i> , 2021, 21, 331.	1.1	1
527	Low level of stromal lectin-like oxidized LDL receptor 1 and CD8 + cytotoxic T lymphocytes indicate poor prognosis of colorectal cancer. <i>Cancer Reports</i> , 2021, 4, e1364.	0.6	5
528	Clinical and immunological effects of mRNA vaccines in malignant diseases. <i>Molecular Cancer</i> , 2021, 20, 52.	7.9	90
529	Tumor-infiltrating plasmacytoid dendritic cells are associated with survival in human colon cancer. , 2021, 9, e001813.		57
530	Plinabulin, a Distinct Microtubule-Targeting Chemotherapy, Promotes M1-Like Macrophage Polarization and Anti-tumor Immunity. <i>Frontiers in Oncology</i> , 2021, 11, 644608.	1.3	19
531	Exploring the significance of novel immune-related gene signatures in the prognosis and immune features of pancreatic adenocarcinoma. <i>International Immunopharmacology</i> , 2021, 92, 107359.	1.7	8
532	Immune Regulation of the cGAS-STING Signaling Pathway in the Tumor Microenvironment and Its Clinical Application. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 1501-1516.	1.0	12
533	Renal cell carcinoma pathology in 2021: a new need for renal cancer immune profiling™. <i>Current Opinion in Urology</i> , 2021, 31, 228-235.	0.9	5
534	ASO Author Reflections: Optimization of Tumor Therapy for the Specific Immune Microenvironment of Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 6451-6452.	0.7	1
535	Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data. <i>Aging</i> , 2021, 13, 11257-11280.	1.4	11

#	ARTICLE	IF	CITATIONS
536	Harnessing TH9 cells in cancer immunotherapy. <i>Seminars in Immunology</i> , 2021, 52, 101477.	2.7	3
537	The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers. <i>Molecules</i> , 2021, 26, 2201.	1.7	23
539	IL-22-mediates Cross-talk between Tumor Cells and Immune Cells Associated with Favorable Prognosis in Human Colorectal Cancer. , 2021, 3, 118-121.		2
540	CD244 ⁺ polymorphonuclear myeloid-derived suppressor cells reflect the status of peritoneal dissemination in a colon cancer mouse model. <i>Oncology Reports</i> , 2021, 45, .	1.2	6
541	Endogenous Stimuli-Activatable Nanomedicine for Immune Theranostics for Cancer. <i>Advanced Functional Materials</i> , 2021, 31, 2100386.	7.8	36
542	Advances in immunotherapy for hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 525-543.	8.2	609
543	Comprehensive Analysis of Myeloid Signature Genes in Head and Neck Squamous Cell Carcinoma to Predict the Prognosis and Immune Infiltration. <i>Frontiers in Immunology</i> , 2021, 12, 659184.	2.2	13
544	Apatinib combined with PD-L1 blockade synergistically enhances antitumor immune responses and promotes HEV formation in gastric cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2209-2222.	1.2	15
545	Delta-Radiomics Signature For Prediction Of Survival In Advanced Nslc Patients Treated With Immunotherapy. , 2021, , .		1
546	An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. <i>Nature Communications</i> , 2021, 12, 2301.	5.8	159
547	The Current Landscape of Immune Checkpoint Blockade in Glioblastoma. <i>Neurosurgery Clinics of North America</i> , 2021, 32, 235-248.	0.8	8
548	Assessment of Immunological Features in Muscle-Invasive Bladder Cancer Prognosis Using Ensemble Learning. <i>Cancers</i> , 2021, 13, 1624.	1.7	17
549	Therapeutic Targeting of the Tumor Microenvironment. <i>Cancer Discovery</i> , 2021, 11, 933-959.	7.7	646
550	Tumor cell intrinsic RON signaling suppresses innate immune responses in breast cancer through inhibition of IRAK4 signaling. <i>Cancer Letters</i> , 2021, 503, 75-90.	3.2	11
551	Natural Polysaccharides and Their Derivates: A Promising Natural Adjuvant for Tumor Immunotherapy. <i>Frontiers in Pharmacology</i> , 2021, 12, 621813.	1.6	22
552	Identification of Immune-Related LncRNA Pairs for Predicting Prognosis and Immunotherapeutic Response in Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 658631.	2.2	10
553	Screening and Identification of Key Microenvironment-Related Genes in Non-functioning Pituitary Adenoma. <i>Frontiers in Genetics</i> , 2021, 12, 627117.	1.1	6
555	Review of Prognostic Expression Markers for Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 643065.	1.3	26

#	ARTICLE	IF	CITATIONS
557	CD74+ macrophages are associated with favorable prognosis and immune contexture in hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 57-69.	2.0	15
558	Beneficial autoimmunity improves cancer prognosis. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 591-602.	12.5	63
559	Impact of Immunotherapy on CD4 T Cell Phenotypes and Function in Cancer. <i>Vaccines</i> , 2021, 9, 454.	2.1	11
560	Development of Exhaustion and Acquisition of Regulatory Function by Infiltrating CD8+CD28 ^{hi} T Lymphocytes Dictate Clinical Outcome in Head and Neck Cancer. <i>Cancers</i> , 2021, 13, 2234.	1.7	8
561	Prognostic and Predictive Value of Immune-Related Gene Pair Signature in Primary Lower-Grade Glioma Patients. <i>Frontiers in Oncology</i> , 2021, 11, 665870.	1.3	3
562	A six-gene signature related with tumor mutation burden for predicting lymph node metastasis in breast cancer. <i>Translational Cancer Research</i> , 2021, 10, 2229-2246.	0.4	3
563	Glioma-Derived Extracellular Vesicles “Far More Than Local Mediators. <i>Frontiers in Immunology</i> , 2021, 12, 679954.	2.2	11
564	Nanoparticle-enabled innate immune stimulation activates endogenous tumor-infiltrating T cells with broad antigen specificities. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	14
565	Imaging of T-cell Responses in the Context of Cancer Immunotherapy. <i>Cancer Immunology Research</i> , 2021, 9, 490-502.	1.6	8
566	Radiomic biomarkers of tumor immune biology and immunotherapy response. <i>Clinical and Translational Radiation Oncology</i> , 2021, 28, 97-115.	0.9	22
567	How metabolism bridles cytotoxic CD8+ T cells through epigenetic modifications. <i>Trends in Immunology</i> , 2021, 42, 401-417.	2.9	18
568	Tertiary Lymphoid Structures as a Predictive Biomarker of Response to Cancer Immunotherapies. <i>Frontiers in Immunology</i> , 2021, 12, 674565.	2.2	28
569	Intratumoral CXCR5+CD8+T associates with favorable clinical outcomes and immunogenic contexture in gastric cancer. <i>Nature Communications</i> , 2021, 12, 3080.	5.8	34
570	Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features. <i>Nature Communications</i> , 2021, 12, 2722.	5.8	74
571	Turning tumors from cold to inflamed to improve immunotherapy response. <i>Cancer Treatment Reviews</i> , 2021, 101, 102227.	3.4	42
572	In Situ Vaccination as a Strategy to Modulate the Immune Microenvironment of Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 650486.	2.2	26
573	Applications of single-cell and bulk RNA sequencing in onco-immunology. <i>European Journal of Cancer</i> , 2021, 149, 193-210.	1.3	62
574	A Cancer-Specific Qualitative Method for Estimating the Proportion of Tumor-Infiltrating Immune Cells. <i>Frontiers in Immunology</i> , 2021, 12, 672031.	2.2	1

#	ARTICLE	IF	CITATIONS
575	Impact of PD-L1 and PD-1 Expression on the Prognostic Significance of CD8+ Tumor-Infiltrating Lymphocytes in Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 680973.	2.2	20
576	Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. <i>Cancer Immunology Research</i> , 2021, 9, 891-908.	1.6	43
577	M5C regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2021, 10, 2172-2192.	1.3	15
578	Heterogeneity of Colorectal Cancer Progression: Molecular Gas and Brakes. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5246.	1.8	9
579	Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. <i>Cancer Cell</i> , 2021, 39, 632-648.e8.	7.7	230
580	The Combination Immunotherapy of TLR9 Agonist and OX40 Agonist via Intratumoural Injection for Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 529-543.	1.8	11
581	Distinct Patterns of Myeloid Cell Infiltration in Patients With hrHPV-Positive and hrHPV-Negative Penile Squamous Cell Carcinoma: The Importance of Assessing Myeloid Cell Densities Within the Spatial Context of the Tumor. <i>Frontiers in Immunology</i> , 2021, 12, 682030.	2.2	4
582	Correlation between the number of viable tumor cells and immune cells in the tumor microenvironment in non-small cell lung cancer after induction therapy. <i>Pathology International</i> , 2021, 71, 512-520.	0.6	0
583	The Comprehensive "Omics" Approach from Metabolomics to Advanced Omics for Development of Immune Checkpoint Inhibitors: Potential Strategies for Next Generation of Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6932.	1.8	9
584	Current Perspectives on B Lymphocytes in the Immunobiology of Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 647854.	1.3	17
585	Cancer vaccines: An unkept promise?. <i>Drug Discovery Today</i> , 2021, 26, 1347-1352.	3.2	7
587	CD3+, CD8+, CD4+ and FOXP3+ T Cells in the Immune Microenvironment of Small Bowel Neuroendocrine Tumors. <i>Diseases (Basel, Switzerland)</i> , 2021, 9, 42.	1.0	4
588	Valeur pronostique et prédictive de l'Immunoscore dans les cancers du colon et de la vessie. <i>HEGEL - HEpato-GastroEntérologie Libérale</i> , 2021, N° 2, 113-118.	0.0	0
589	Latency-associated peptide identifies therapeutically resistant muscle-invasive bladder cancer with poor prognosis. <i>Cancer Immunology, Immunotherapy</i> , 2021, , 1.	2.0	2
590	Checkpoint inhibitor therapy for metastatic triple-negative breast cancer. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 537-547.	2.7	58
591	Site-Dependent Immune Escape Due to Impaired Dendritic Cell Cross-Priming. <i>Cancer Immunology Research</i> , 2021, 9, 877-890.	1.6	14
592	Epigenetic Reprogramming of CD4+ Helper T Cells as a Strategy to Improve Anticancer Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 669992.	2.2	18
593	Evaluation of tumor immune contexture among intrinsic molecular subtypes helps to predict outcome in early breast cancer. , 2021, 9, e002036.		4

#	ARTICLE	IF	CITATIONS
594	HLA-DR and CD74 Expression and the Immune Microenvironment in Renal Cell Carcinoma. <i>Anticancer Research</i> , 2021, 41, 2841-2848.	0.5	1
595	ATP and cancer immunosurveillance. <i>EMBO Journal</i> , 2021, 40, e108130.	3.5	105
596	Challenges and Opportunities in the Statistical Analysis of Multiplex Immunofluorescence Data. <i>Cancers</i> , 2021, 13, 3031.	1.7	21
597	Multiplexed digital spatial profiling of invasive breast tumors from Black and White women. <i>Molecular Oncology</i> , 2022, 16, 54-68.	2.1	12
598	Ovarian Cancer Immunotherapy and Personalized Medicine. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6532.	1.8	128
599	Regulatory Network Analysis of Mutated Genes Based on Multi-Omics Data Reveals the Exclusive Features in Tumor Immune Microenvironment Between Left-Sided and Right-Sided Colon Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 685515.	1.3	10
600	Targeting Cancer Heterogeneity with Immune Responses Driven by Oncolytic Peptides. <i>Trends in Cancer</i> , 2021, 7, 557-572.	3.8	33
601	Metabolic features of cancer cells impact immunosurveillance. , 2021, 9, e002362.		11
602	Tumor Microenvironment Subtypes and Immune-Related Signatures for the Prognosis of Breast Cancer. <i>BioMed Research International</i> , 2021, 2021, 1-12.	0.9	2
603	NIR-Responsive Inorganic 2D Nanomaterials for Cancer Photothermal Therapy: Recent Advances and Future Challenges. <i>Advanced Functional Materials</i> , 2021, 31, 2101625.	7.8	126
604	Defective HLA Class I Expression and Patterns of Lymphocyte Infiltration in Chordoma Tumors. <i>Clinical Orthopaedics and Related Research</i> , 2021, 479, 1373-1382.	0.7	11
605	Intratumoral talimogene laherparepvec injection with concurrent preoperative radiation in patients with locally advanced soft-tissue sarcoma of the trunk and extremities: phase IB/II trial. , 2021, 9, e003119.		10
606	CXCL13 shapes tertiary lymphoid structures and promotes response to immunotherapy in bladder cancer. <i>European Journal of Cancer</i> , 2021, 151, 245-248.	1.3	14
607	Identification of CXCL10-Relevant Tumor Microenvironment Characterization and Clinical Outcome in Ovarian Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 678747.	1.1	5
608	Comprehensive Characterization of Immune Landscape Based on Epithelial-Mesenchymal Transition Signature in OSCC: Implication for Prognosis and Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 587862.	1.3	6
609	Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1211-1223.	0.5	17
610	CD8+ T cell differentiation and dysfunction in cancer. <i>Nature Reviews Immunology</i> , 2022, 22, 209-223.	10.6	345
611	Multiplexed single-cell pathology reveals the association of CD8 T-cell heterogeneity with prognostic outcomes in renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3001-3013.	2.0	17

#	ARTICLE	IF	CITATIONS
612	Narrative review: molecular and genetic profiling of oligometastatic non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 3351-3368.	1.3	1
613	Lipophilic recombinant-protein insertion endows lymphocytes with enhanced targeting-infiltration ability in EGFR positive cancer. <i>Cellular Immunology</i> , 2021, 365, 104376.	1.4	0
614	Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma. <i>Nature Communications</i> , 2021, 12, 4127.	5.8	59
615	Evolving Dynamic Biomarkers for Prediction of Immune Responses to Checkpoint Inhibitors in Cancer. , 0, , .		4
616	Deep Sequencing of T-Cell Receptors for Monitoring Peripheral CD8+ T Cells in Chinese Advanced Non-Small-Cell Lung Cancer Patients Treated With the Anti-PD-L1 Antibody. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 679130.	1.6	11
617	Interleukin-2 inducible T-cell kinase: a potential prognostic biomarker and tumor microenvironment remodeling indicator for hepatocellular carcinoma. <i>Aging</i> , 2021, 13, 18620-18644.	1.4	2
618	Pretreatment Absolute Lymphocyte Count and Neutrophil-to-lymphocyte Ratio Are Prognostic Factors for Stage III Breast Cancer. <i>Anticancer Research</i> , 2021, 41, 3625-3634.	0.5	7
619	Identification and characterization of prognosis-related genes in the tumor microenvironment of esophageal squamous cell carcinoma. <i>International Immunopharmacology</i> , 2021, 96, 107616.	1.7	5
620	Development of a Deep-Learning Pipeline to Recognize and Characterize Macrophages in Colo-Rectal Liver Metastasis. <i>Cancers</i> , 2021, 13, 3313.	1.7	8
621	T Cells Retain Pivotal Antitumoral Functions under Tumor-Treating Electric Fields. <i>Journal of Immunology</i> , 2021, 207, 709-719.	0.4	11
622	PSMC5 Promotes Proliferation and Metastasis of Colorectal Cancer by Activating Epithelial-Mesenchymal Transition Signaling and Modulating Immune Infiltrating Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 657917.	1.8	11
623	Digital Pathology Scoring of Immunohistochemical Staining Reliably Identifies Prognostic Markers and Anatomical Associations in a Large Cohort of Oral Cancers. <i>Frontiers in Oncology</i> , 2021, 11, 712944.	1.3	7
624	Improving the therapeutic ratio of radiotherapy against radioresistant cancers: Leveraging on novel artificial intelligence-based approaches for drug combination discovery. <i>Cancer Letters</i> , 2021, 511, 56-67.	3.2	11
625	The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment. <i>Bioactive Materials</i> , 2021, 6, 1973-1987.	8.6	343
626	Predictive Value of the Systemic Immune-Inflammation Index for Intravenous Immunoglobulin Resistance and Cardiovascular Complications in Kawasaki Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 711007.	1.1	16
627	Second Primary Cancers After Liver, Gallbladder and Bile Duct Cancers, and These Cancers as Second Primary Cancers. <i>Clinical Epidemiology</i> , 2021, Volume 13, 683-691.	1.5	6
628	Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer. , 2021, 9, e002467.		97
629	Poor Prognosis and Therapeutic Responses in LILRB1-Expressing M2 Macrophages-Enriched Gastric Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 668707.	1.3	5

#	ARTICLE	IF	CITATIONS
630	NK cell and ILC heterogeneity in colorectal cancer. New perspectives from high dimensional data. <i>Molecular Aspects of Medicine</i> , 2021, 80, 100967.	2.7	7
631	Rational Design, Pharmacomodulation, and Synthesis of [⁶⁸ Ga]Ga-Alb-FAPtp-01, a Selective Tumor-Associated Fibroblast Activation Protein Tracer for PET Imaging of Glioma. <i>ACS Sensors</i> , 2021, 6, 3424-3435.	4.0	15
632	NOTCH signaling: Journey of an evolutionarily conserved pathway in driving tumor progression and its modulation as a therapeutic target. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 164, 103403.	2.0	17
633	Clearing up Clear Cell: Clarifying the Immuno-Oncology Treatment Landscape for Metastatic Clear Cell RCC. <i>Cancers</i> , 2021, 13, 4140.	1.7	14
634	Analysis of Bulk RNA Sequencing Data Reveals Novel Transcription Factors Associated With Immune Infiltration Among Multiple Cancers. <i>Frontiers in Immunology</i> , 2021, 12, 644350.	2.2	6
635	Novel insights on gut microbiota manipulation and immune checkpoint inhibition in cancer (Review). <i>International Journal of Oncology</i> , 2021, 59, .	1.4	17
636	Interpretable systems biomarkers predict response to immune-checkpoint inhibitors. <i>Patterns</i> , 2021, 2, 100293.	3.1	47
638	N6-methyladenosine (m6A) regulatory gene divides hepatocellular carcinoma into three subtypes. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 1860-1872.	0.6	6
639	Pan-Cancer Analysis of Immune Complement Signature C3/C5/C3AR1/C5AR1 in Association with Tumor Immune Evasion and Therapy Resistance. <i>Cancers</i> , 2021, 13, 4124.	1.7	17
640	The relationship between CD204 M2-polarized tumour-associated macrophages (TAMs), tumour-infiltrating lymphocytes (TILs), and microglial activation in glioblastoma microenvironment: a novel immune checkpoint receptor target. <i>Discover Oncology</i> , 2021, 12, 28.	0.8	8
642	Genetic Variants and Tumor Immune Microenvironment: Clues for Targeted Therapies in Inflammatory Breast Cancer (IBC). <i>International Journal of Molecular Sciences</i> , 2021, 22, 8924.	1.8	1
643	Identification of LOXL3-associating immune infiltration landscape and prognostic value in hepatocellular carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 1153-1165.	1.4	13
644	Evaluating prognostic value and relevant gene signatures of tumor microenvironment characterization in esophageal carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 1228-1240.	0.6	4
645	Systemic Inflammation Associates With a Myeloid Inflamed Tumor Microenvironment in Primary Resected Colon Cancer—May Cold Tumors Simply Be Too Hot?. <i>Frontiers in Immunology</i> , 2021, 12, 716342.	2.2	11
646	Identification of Biomarkers for Cervical Cancer Radiotherapy Resistance Based on RNA Sequencing Data. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 724172.	1.8	9
647	Integrated Analysis of the Immune Infiltrates and PD-L1 Expression of N6-Methyladenosine-Related Long Non-Coding RNAs in Colorectal Cancer. <i>International Journal of General Medicine</i> , 2021, Volume 14, 5017-5028.	0.8	5
648	BTLA-HVEM Couple in Health and Diseases: Insights for Immunotherapy in Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 682007.	1.3	29
649	Prognostic Value of Tumor-Infiltrating Lymphocytes in Sinonasal Mucosal Melanoma. <i>Laryngoscope</i> , 2021, , .	1.1	7

#	ARTICLE	IF	CITATIONS
650	Interleukin-1 in tumor progression, therapy, and prevention. <i>Cancer Cell</i> , 2021, 39, 1023-1027.	7.7	47
651	Nanomedicines modulating myeloid-derived suppressor cells for improving cancer immunotherapy. <i>Nano Today</i> , 2021, 39, 101163.	6.2	18
652	Linking Immunity with Genomics in Sarcomas: Is Genomic Complexity an Immunogenic Trigger?. <i>Biomedicines</i> , 2021, 9, 1048.	1.4	6
653	Natural Killer Cells and Type 1 Innate Lymphoid Cells in Hepatocellular Carcinoma: Current Knowledge and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9044.	1.8	7
654	Paving the Way for Immunotherapy in Pediatric Acute Myeloid Leukemia: Current Knowledge and the Way Forward. <i>Cancers</i> , 2021, 13, 4364.	1.7	5
655	Peripheral Blood Lymphocyte Percentage May Predict Chemotolerance and Survival in Patients with Advanced Pancreatic Cancer. Association between Adaptive Immunity and Nutritional State. <i>Current Oncology</i> , 2021, 28, 3280-3296.	0.9	2
656	Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1267-1288.	0.5	77
657	Progression on the Roles and Mechanisms of Tumor-Infiltrating T Lymphocytes in Patients With Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 729705.	2.2	46
658	Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: A TAM-pting approach. , 2022, 231, 107986.		30
659	Personalized models of heterogeneous 3D epithelial tumor microenvironments: Ovarian cancer as a model. <i>Acta Biomaterialia</i> , 2021, 132, 401-420.	4.1	9
660	KAT2B is an immune infiltration-associated biomarker predicting prognosis and response to immunotherapy in non-small cell lung cancer. <i>Investigational New Drugs</i> , 2022, 40, 43-57.	1.2	10
661	Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	20
662	Artificial intelligence for solid tumour diagnosis in digital pathology. <i>British Journal of Pharmacology</i> , 2021, 178, 4291-4315.	2.7	14
663	Tumor Immunology and Immunotherapy of Non-Small-Cell Lung Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2022, 12, a037895.	2.9	24
664	NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images. <i>Cancers</i> , 2021, 13, 4543.	1.7	14
665	Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer. <i>Cell</i> , 2021, 184, 5015-5030.e16.	13.5	102
666	Prognostic Value of Inflammatory Biomarkers in Patients With Stage I Lung Adenocarcinoma Treated With Surgical Dissection. <i>Frontiers in Oncology</i> , 2021, 11, 711206.	1.3	18
667	Tumour antigen-induced T cell exhaustion – the archenemy of immune-hot malignancies. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 749-750.	12.5	20

#	ARTICLE	IF	CITATIONS
668	Considerations for the delivery of STING ligands in cancer immunotherapy. <i>Journal of Controlled Release</i> , 2021, 339, 235-247.	4.8	18
669	Heparanase (HPSE) Associates with the Tumor Immune Microenvironment in Colorectal Cancer. <i>Processes</i> , 2021, 9, 1605.	1.3	2
670	Identification of Prognostic Metabolism-Related Genes in Clear Cell Renal Cell Carcinoma. <i>Journal of Oncology</i> , 2021, 2021, 1-13.	0.6	9
671	NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. <i>Journal of Hepatology</i> , 2022, 76, 446-457.	1.8	121
672	Effector T ^h 1 responses unleashed by regulatory T ^h 1 ablation exacerbate oral squamous cell carcinoma. <i>Cell Reports Medicine</i> , 2021, 2, 100399.	3.3	11
673	TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 667875.	2.2	11
674	Malignant Tumor Purity Reveals the Driven and Prognostic Role of CD3E in Low-Grade Glioma Microenvironment. <i>Frontiers in Oncology</i> , 2021, 11, 676124.	1.3	10
675	Sleep Deprivation Disturbs Immune Surveillance and Promotes the Progression of Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 727959.	2.2	12
676	Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 703802.	1.3	10
677	Solute carrier family 16 member 5 downregulation and its methylation might serve as a prognostic indicator of prostate cancer. <i>IUBMB Life</i> , 2021, 73, 1363-1377.	1.5	4
678	A gene expression-based immune content predictor for survival and postoperative radiotherapy response in head and neck cancer. <i>Molecular Therapy - Oncolytics</i> , 2021, 22, 380-387.	2.0	0
679	CD8+ T cells from experimental in situ breast carcinoma interfere with bone homeostasis. <i>Bone</i> , 2021, 150, 116014.	1.4	9
680	Identification of an Immune-Related Long Noncoding RNA Pairs Model to Predict Survival and Immune Features in Gastric Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 726716.	1.8	6
681	DNA Methylation Regulator-Mediated Modification Patterns Define the Distinct Tumor Microenvironment in Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 734873.	1.3	2
682	m6A Methylation Modification Patterns and Tumor Microenvironment Infiltration Characterization in Pancreatic Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 739768.	2.2	9
683	Refining patient selection for breast cancer immunotherapy: beyond PD-L1. <i>ESMO Open</i> , 2021, 6, 100257.	2.0	13
684	TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells. <i>Oral Oncology</i> , 2021, 121, 105472.	0.8	30
685	The clinical significance of tertiary lymphoid structure and its relationship with peripheral blood characteristics in patients with surgically resected non-small cell lung cancer: a single-center, retrospective study. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1129-1137.	2.0	9

#	ARTICLE	IF	CITATIONS
686	Can interruption of innate immune recognition-mediated emergency myelopoiesis impede tumor progression?. <i>Medical Hypotheses</i> , 2021, 155, 110663.	0.8	2
687	Autophagy inhibition in breast cancer cells induces ROS-mediated MIF expression and M1 macrophage polarization. <i>Cellular Signalling</i> , 2021, 86, 110075.	1.7	15
688	Current trends and future perspectives of nanomedicine for the management of colon cancer. <i>European Journal of Pharmacology</i> , 2021, 910, 174464.	1.7	32
689	Impact of intratumoural CD73 expression on prognosis and therapeutic response in patients with gastric cancer. <i>European Journal of Cancer</i> , 2021, 157, 114-123.	1.3	15
690	Endothelial cell metabolism: A potential target to improve tumor immunity. <i>Current Opinion in Systems Biology</i> , 2021, 28, 100376.	1.3	2
691	Metabolic reprogramming and immunity in cancer. , 2022, , 137-196.		1
692	Intrinsic and acquired cancer immunotherapy resistance. , 2022, , 463-497.		0
693	Molecular oncology in gynecologic cancer. , 2022, , 606-617.e3.		0
694	Immune checkpoint blockade therapy in high-grade glioma. , 2022, , 91-108.		0
695	Mutational Signatures Driven by Epigenetic Determinants Enable the Stratification of Patients with Gastric Cancer for Therapeutic Intervention. <i>Cancers</i> , 2021, 13, 490.	1.7	5
696	Tumor Microenvironment Status Predicts the Efficacy of Postoperative Chemotherapy or Radiochemotherapy in Resected Gastric Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 609337.	2.2	13
697	Hexokinase 3 dysfunction promotes tumorigenesis and immune escape by upregulating monocyte/macrophage infiltration into the clear cell renal cell carcinoma microenvironment. <i>International Journal of Biological Sciences</i> , 2021, 17, 2205-2222.	2.6	36
698	Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapies. <i>Oncolmmunology</i> , 2021, 10, 1900508.	2.1	57
699	Antitumour immunity regulated by aberrant ERBB family signalling. <i>Nature Reviews Cancer</i> , 2021, 21, 181-197.	12.8	141
701	Association of TRF2 expression and myeloid-derived suppressor cells infiltration with clinical outcome of patients with cutaneous melanoma. <i>Oncolmmunology</i> , 2021, 10, 1901446.	2.1	2
702	Colorectal Cancer: A Model for the Study of Cancer Immunology. , 2021, , 15-30.		0
703	Exploration of the immune cell infiltration-related gene signature in the prognosis of melanoma. <i>Aging</i> , 2021, 13, 3459-3482.	1.4	19
704	Identification and validation of a prognostic signature and combination drug therapy for immunotherapy of head and neck squamous cell carcinoma. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 1263-1276.	1.9	12

#	ARTICLE	IF	CITATIONS
705	Weakly Supervised Deep Ordinal Cox Model for Survival Prediction From Whole-Slide Pathological Images. <i>IEEE Transactions on Medical Imaging</i> , 2021, 40, 3739-3747.	5.4	26
706	CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1965-1976.	2.0	14
707	Beyond conventional immune-checkpoint inhibition – novel immunotherapies for renal cell carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 199-214.	12.5	179
708	Increased tumor-infiltrating plasmacytoid dendritic cells promote cancer cell proliferation and invasion via TNF- α /NF- κ B/CXCR-4 pathway in oral squamous cell carcinoma. <i>Journal of Cancer</i> , 2021, 12, 3045-3056.	1.2	19
709	Immunedeconv: An R Package for Unified Access to Computational Methods for Estimating Immune Cell Fractions from Bulk RNA-Sequencing Data. <i>Methods in Molecular Biology</i> , 2020, 2120, 223-232.	0.4	120
710	Methods to Detect Immunogenic Cell Death In Vivo. <i>Methods in Molecular Biology</i> , 2020, 2055, 433-452.	0.4	5
711	Genetic Instability Markers in Cancer. <i>Methods in Molecular Biology</i> , 2020, 2055, 133-154.	0.4	2
712	Detection of Tumor Antigen-Specific T-Cell Responses After Oncolytic Vaccination. <i>Methods in Molecular Biology</i> , 2020, 2058, 191-211.	0.4	7
713	Janus or Hydra: The Many Faces of T Helper Cells in the Human Tumour Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1224, 35-51.	0.8	10
714	The Relevance of Notch Signaling in Cancer Progression. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1287, 169-181.	0.8	18
715	Autophagy and Tumorigenesis. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1207, 275-299.	0.8	17
716	The paratumoral immune cell signature reveals the potential for the implementation of immunotherapy in esophageal carcinoma patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1979-1992.	1.2	12
717	IL-36 family cytokines in protective versus destructive inflammation. <i>Cellular Signalling</i> , 2020, 75, 109773.	1.7	29
718	Emerging theranostic gold nanostructures to combat cancer: Novel probes for Combinatorial Immunotherapy and Photothermal Therapy. <i>Cancer Treatment and Research Communications</i> , 2020, 25, 100258.	0.7	24
719	Anti-NKG2D single domain-based antibodies for the modulation of anti-tumor immune response. <i>Onc Immunology</i> , 2021, 10, 1854529.	2.1	19
720	Macrophage morphology correlates with single-cell diversity and prognosis in colorectal liver metastasis. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	99
721	B cells and cancer: To B or not to B?. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	91
722	Common risk factors for heart failure and cancer. <i>Cardiovascular Research</i> , 2019, 115, 844-853.	1.8	175

#	ARTICLE	IF	CITATIONS
723	Latency-associated Peptide Identifies Immuno-evasive Subtype Gastric Cancer With Poor Prognosis and Inferior Chemotherapeutic Responsiveness. <i>Annals of Surgery</i> , 2022, 275, e163-e173.	2.1	17
724	Poor Clinical Outcomes and Immuno-evasive Contexture in Intratumoral IL-10-Producing Macrophages Enriched Gastric Cancer Patients. <i>Annals of Surgery</i> , 2022, 275, e626-e635.	2.1	95
738	Phagocytic function of tumor-associated macrophages as a key determinant of tumor progression control: a review. , 2020, 8, e001408.		100
739	Natural killer cell and stroma abundance are independently prognostic and predict gastric cancer chemotherapy benefit. <i>JCI Insight</i> , 2020, 5, .	2.3	50
740	IL-32 ^{Δ3} potentiates tumor immunity in melanoma. <i>JCI Insight</i> , 2020, 5, .	2.3	20
741	Myeloid signature reveals immune contexture and predicts the prognosis of hepatocellular carcinoma. <i>Journal of Clinical Investigation</i> , 2020, 130, 4679-4693.	3.9	42
742	Selective SIRP ^Δ blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance. <i>Journal of Clinical Investigation</i> , 2020, 130, 6109-6123.	3.9	53
743	Immune profiling of pediatric solid tumors. <i>Journal of Clinical Investigation</i> , 2020, 130, 3391-3402.	3.9	27
744	Inhibition of transcription by dactinomycin reveals a new characteristic of immunogenic cell stress. <i>EMBO Molecular Medicine</i> , 2020, 12, e11622.	3.3	67
745	Clinical and transcriptional signatures of human CD204 reveal an applicable marker for the protumor phenotype of tumor-associated macrophages in breast cancer. <i>Aging</i> , 2019, 11, 10883-10901.	1.4	8
746	A three-gene signature based on tumour microenvironment predicts overall survival of osteosarcoma in adolescents and young adults. <i>Aging</i> , 2021, 13, 619-645.	1.4	10
747	Lysosome-targeting agents in cancer therapy. <i>Oncotarget</i> , 2017, 8, 112168-112169.	0.8	13
748	Virus and tumor microenvironment induced ER stress and unfolded protein response: from complexity to therapeutics. <i>Oncotarget</i> , 2018, 9, 31920-31936.	0.8	9
749	Prognostic significance of tumor genotypes and CD8+ infiltrates in stage I-III colorectal cancer. <i>Oncotarget</i> , 2018, 9, 35623-35638.	0.8	15
750	Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives. <i>Journal of Cancer Metastasis and Treatment</i> , 2018, 4, 12.	0.5	5
751	https://cdrjournal.com/article/view/3531 . , 2020, 3, 454-471.		4
752	Relevance of arm somatic copy number alterations for oncologic outcomes and tumor immune microenvironment in clear cell renal cell carcinoma. <i>Annals of Translational Medicine</i> , 2019, 7, 646-646.	0.7	5
753	PTPRO predicts patient prognosis and correlates with immune infiltrates in human clear cell renal cell carcinoma. <i>Translational Cancer Research</i> , 2020, 9, 4800-4810.	0.4	10

#	ARTICLE	IF	CITATIONS
754	Co-signaling receptors regulate T-cell plasticity and immune tolerance. <i>Frontiers in Bioscience - Landmark</i> , 2019, 24, 96-132.	3.0	54
755	Apparent Lack of BRAFV600E Derived HLA Class I Presented Neoantigens Hampers Neoplastic Cell Targeting by CD8+ T Cells in Langerhans Cell Histiocytosis. <i>Frontiers in Immunology</i> , 2019, 10, 3045.	2.2	4
756	Innate Lymphoid Cells in Colorectal Cancers: A Double-Edged Sword. <i>Frontiers in Immunology</i> , 2019, 10, 3080.	2.2	14
757	Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade. <i>Frontiers in Immunology</i> , 2020, 11, 339.	2.2	77
758	Antibiotic-Related Changes in Microbiome: The Hidden Villain behind Colorectal Carcinoma Immunotherapy Failure. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1754.	1.8	19
759	When Molecular-Targeted Agents Meet Immunotherapy: The Opportunities for Soft Tissue Sarcoma. <i>Journal of Immunotherapy and Precision Oncology</i> , 2020, 3, 69-82.	0.6	2
760	Microenvironment Analysis of Prognosis and Molecular Signature of Immune-Related Genes in Lung Adenocarcinoma. <i>Oncology Research</i> , 2020, 28, 561-578.	0.6	13
761	Immune landscape and biomarkers for immuno-oncology in colorectal cancers. <i>Journal of Pathology and Translational Medicine</i> , 2020, 54, 351-360.	0.4	9
762	Topography of cancer-associated immune cells in human solid tumors. <i>ELife</i> , 2018, 7, .	2.8	206
763	Comparative profiling of immune genes improves the prognoses of lower grade gliomas. <i>Cancer Biology and Medicine</i> , 2021, 18, 0-0.	1.4	5
764	Significance of Glasgow Prognostic Scores in NSCLC Patients Treated With Immunotherapy After Platinum-based Cytotoxic Chemotherapy. <i>In Vivo</i> , 2021, 35, 3423-3430.	0.6	2
765	Identification of m6A methyltransferase-related genes predicts prognosis and immune infiltrates in head and neck squamous cell carcinoma. <i>Annals of Translational Medicine</i> , 2021, 9, 1554-1554.	0.7	11
766	Trial watch: intratumoral immunotherapy. <i>Oncolmmunology</i> , 2021, 10, 1984677.	2.1	31
767	Identification of an Immune-Related Prognostic Gene CLEC5A Based on Immune Microenvironment and Risk Modeling of Ovarian Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 746932.	1.8	7
768	Precision diagnostics: Integration of tissue pathology and genomics in cancer. <i>Pathology</i> , 2021, 53, 809-817.	0.3	2
769	Identification of a Prognosis-Related Risk Signature for Bladder Cancer to Predict Survival and Immune Landscapes. <i>Journal of Immunology Research</i> , 2021, 2021, 1-26.	0.9	14
770	Multiparameter persistent homology landscapes identify immune cell spatial patterns in tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	33
771	Prognostic Significance of Circulating Lymphocyte Subsets Before Treatment in Patients with Nasopharyngeal Carcinoma. <i>Cancer Management and Research</i> , 2021, Volume 13, 8109-8120.	0.9	2

#	ARTICLE	IF	CITATIONS
772	Construction and Validation of an Immune-Related Gene Prognostic Index for Esophageal Squamous Cell Carcinoma. <i>BioMed Research International</i> , 2021, 2021, 1-18.	0.9	4
773	In-vitro 3D modelling for charged particle therapy – Uncertainties and opportunities. <i>Advanced Drug Delivery Reviews</i> , 2021, 179, 114018.	6.6	6
774	Prediction of prognosis and immunotherapy response with a robust immune-related lncRNA pair signature in lung adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1295-1311.	2.0	17
775	Prognostic role of tumour-infiltrating lymphocytes and macrophages in relation to MSI, CDX2 and BRAF status: a population-based study of metastatic colorectal cancer patients. <i>British Journal of Cancer</i> , 2022, 126, 48-56.	2.9	8
776	Assessment of immune status of laryngeal squamous cell carcinoma can predict prognosis and guide treatment. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1199-1220.	2.0	10
777	Prognostic Value of Interleukin-32 Expression and Its Correlation with the Infiltration of Natural Killer Cells in Cutaneous Melanoma. <i>Journal of Clinical Medicine</i> , 2021, 10, 4691.	1.0	6
778	P2Y12 Purinergic Receptor and Brain Tumors: Implications on Glioma Microenvironment. <i>Molecules</i> , 2021, 26, 6146.	1.7	7
779	Technical Feasibility and Safety of Repeated CT-guided Trans-thoracic Intratumoral Injection of Gene Modified Cellular Immunotherapy in Metastatic Non-Small Cell Lung Cancer. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100242.	0.6	0
780	Semi-Mechanistic Model for the Antitumor Response of a Combination Cocktail of Immuno-Modulators in Non-Inflamed (Cold) Tumors. <i>Cancers</i> , 2021, 13, 5049.	1.7	2
781	Targeting DNA Repair Response Promotes Immunotherapy in Ovarian Cancer: Rationale and Clinical Application. <i>Frontiers in Immunology</i> , 2021, 12, 661115.	2.2	7
782	An Immune-Related Gene Prognostic Index for Triple-Negative Breast Cancer Integrates Multiple Aspects of Tumor-Immune Microenvironment. <i>Cancers</i> , 2021, 13, 5342.	1.7	15
783	Cisplatin Reduces the Frequencies of Radiotherapy-Induced Micronuclei in Peripheral Blood Lymphocytes of Patients with Gynaecological Cancer: Possible Implications for the Risk of Second Malignant Neoplasms. <i>Cells</i> , 2021, 10, 2709.	1.8	3
784	Prognostic value of peripheral naive CD8 ⁺ T cells in oligometastatic non-small-cell lung cancer. <i>Future Oncology</i> , 2022, 18, 55-65.	1.1	3
789	Letter to the Editor. Prognostic molecular panel for skull base chordoma. <i>Journal of Neurosurgery</i> , 2019, 130, 1767-1769.	0.9	0
794	Immunotherapy in Pediatric Solid Tumors. <i>Clinical Pediatric Hematology-Oncology</i> , 2020, 27, 22-31.	0.0	1
796	A Seven-Gene Signature with Close Immune Correlation Was Identified for Survival Prediction of Lung Adenocarcinoma. <i>Medical Science Monitor</i> , 2020, 26, e924269.	0.5	3
797	The Epithelial and Stromal Immune Microenvironment in Gastric Cancer: A Comprehensive Analysis Reveals Prognostic Factors with Digital Cytometry. <i>Cancers</i> , 2021, 13, 5382.	1.7	2
798	m6A-Mediated Tumor Invasion and Methylation Modification in Breast Cancer Microenvironment. <i>Journal of Oncology</i> , 2021, 2021, 1-17.	0.6	10

#	ARTICLE	IF	CITATIONS
799	Predictive Value of Baseline [18F]FDG PET/CT for Response to Systemic Therapy in Patients with Advanced Melanoma. <i>Journal of Clinical Medicine</i> , 2021, 10, 4994.	1.0	4
800	Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy. , 2021, 9, e003671.		15
801	Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. <i>Cancer Cell</i> , 2021, 39, 1497-1518.e11.	7.7	126
802	Nanotechnology-based products for cancer immunotherapy. <i>Molecular Biology Reports</i> , 2022, 49, 1389-1412.	1.0	7
803	Lack of CD8 ⁺ T cell effector differentiation during priming mediates checkpoint blockade resistance in non-small cell lung cancer. <i>Science Immunology</i> , 2021, 6, eabi8800.	5.6	58
804	Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers. <i>Cancers</i> , 2021, 13, 5415.	1.7	13
805	Development of immune gene pair-based signature predictive of prognosis and immunotherapy in esophageal cancer. <i>Annals of Translational Medicine</i> , 2021, 9, 1591-1591.	0.7	4
806	Photosynthetic microorganisms coupled photodynamic therapy for enhanced antitumor immune effect. <i>Bioactive Materials</i> , 2022, 12, 97-106.	8.6	23
807	Highlights of Immunomodulation in Salmonella-Based Cancer Therapy. <i>Biomedicines</i> , 2021, 9, 1566.	1.4	4
808	Identification of an Immune-Related Signature Predicting Survival Risk and Immune Microenvironment in Gastric Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 687473.	1.8	9
811	Fighting microbial pathogens by integrating host ecosystem interactions and evolution. <i>BioEssays</i> , 2021, 43, 2000272.	1.2	5
812	Tight Interplay Between Therapeutic Monoclonal Antibodies and the Tumour Microenvironment in Cancer Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1277, 127-141.	0.8	0
813	T Cell Receptor Engineered T Cell Therapy in Oncology. , 2020, , 377-408.		0
814	Immuno-Oncology of Colorectal Cancer. <i>Diagnostics and Therapeutic Advances in GI Malignancies</i> , 2020, , 183-204.	0.2	0
815	Tertiary Lymphoid Structures and Cancer Prognosis (Brief Review). <i>Kreativna Ā Hirurgi Ā I Onkologi Ā</i> , 2020, 9, 293-296.	0.1	0
816	Dynamic label-free in vivo imaging of tumor-immune microenvironment (TiME) and microvasculature features in skin cancers with reflectance confocal microscopy (RCM). , 2020, , .		0
817	In Silico Cell-Type Deconvolution Methods in Cancer Immunotherapy. <i>Methods in Molecular Biology</i> , 2020, 2120, 213-222.	0.4	3
818	Immunopathology and Immunotherapy for Breast Cancer. , 2020, , 541-555.		1

#	ARTICLE	IF	CITATIONS
819	Activation vs. Organization: Prognostic Implications of T and B Cell Features of the PDAC Microenvironment. Lecture Notes in Computer Science, 2020, , 44-55.	1.0	0
823	PD1/PDL1 expression is associated with increased TIM3 expression and tumor-infiltrating T lymphocytes in fibroblastic tumors. Clinical and Translational Oncology, 2022, 24, 586-596.	1.2	1
824	Preoperative Systemic Inflammatory Biomarkers Are Independent Predictors of Disease Recurrence in ER+ HER2- Early Breast Cancer. Frontiers in Oncology, 2021, 11, 773078.	1.3	9
825	Single-Cell Analysis Reveals EP4 as a Target for Restoring T-Cell Infiltration and Sensitizing Prostate Cancer to Immunotherapy. Clinical Cancer Research, 2022, 28, 552-567.	3.2	25
826	Next Generation Tumor Models Guiding Cancer Therapy. Advanced Drug Delivery Reviews, 2021, 179, 114047.	6.6	1
827	SPTAN1, APC, and FGFR3 Mutation Status and APOBEC Mutation Signatures are Predictive of Mitomycin C Response in Non-muscle-invasive Bladder Cancer. European Urology Open Science, 2021, 34, 59-67.	0.2	1
828	Current trends in the immunotherapy of metastatic and recurrent squamous cell carcinoma of the head and neck. Opuholi Golovy I Sei, 2020, 10, 41-47.	0.1	0
829	Definition and review on a category of long non-coding RNA: Atherosclerosis-associated circulating lncRNA (ASCLncRNA). PeerJ, 2020, 8, e10001.	0.9	3
830	CD8 + T Cell Infiltration Predicts Chemoradiosensitivity in Nasopharyngeal or Oropharyngeal Cancer. Laryngoscope, 2021, 131, E1179-E1189.	1.1	9
832	Infiltration of CD8 FOXP3 T cells, CD8 T cells, and FOXP3 T cells in non-small cell lung cancer microenvironment. International Journal of Clinical and Experimental Pathology, 2020, 13, 880-888.	0.5	11
833	Identification and validation of an immune-related gene-based prognostic index for bladder cancer. American Journal of Translational Research (discontinued), 2020, 12, 5188-5204.	0.0	6
834	Prognostic significance of tumor-infiltrating immune cells in muscle-invasive bladder cancer. American Journal of Translational Research (discontinued), 2020, 12, 6524-6536.	0.0	3
835	Why we do what we do. A brief analysis of cancer therapies. EXCLI Journal, 2020, 19, 1401-1413.	0.5	1
836	An immune-related signature that to improve prognosis prediction of breast cancer. American Journal of Cancer Research, 2021, 11, 1267-1285.	1.4	4
837	Glycosylation of Siglec15 promotes immunoescape and tumor growth. American Journal of Cancer Research, 2021, 11, 2291-2302.	1.4	0
838	Nab-paclitaxel promotes the cancer-immunity cycle as a potential immunomodulator. American Journal of Cancer Research, 2021, 11, 3445-3460.	1.4	2
839	Simultaneous disruption of circulating miR-21 and cytotoxic T lymphocytes (CTLs): Prospective diagnostic and prognostic markers for esophageal squamous cell carcinoma (ESCC). Journal of Clinical Laboratory Analysis, 2022, 36, e24125.	0.9	6
840	Updates on Immunotherapy and Immune Landscape in Renal Clear Cell Carcinoma. Cancers, 2021, 13, 5856.	1.7	39

#	ARTICLE	IF	CITATIONS
841	The Hippo Signaling Pathway: The Trader of Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2021, 11, 772134.	1.3	13
842	Neoantigen-driven B cell and CD4 ⁺ follicular helper cell collaboration promotes anti-tumor CD8 T _H cell responses. <i>Cell</i> , 2021, 184, 6101-6118.e13.	13.5	192
843	Tumor purity as a prognosis and immunotherapy relevant feature in cervical cancer. <i>Aging</i> , 2021, 13, 24768-24785.	1.4	22
844	An Immune-Related lncRNA Signature to Predict the Biochemical Recurrence and Immune Landscape in Prostate Cancer. <i>International Journal of General Medicine</i> , 2021, Volume 14, 9031-9049.	0.8	0
845	MicroRNAs: Their Role in Metabolism, Tumor Microenvironment, and Therapeutic Implications in Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2021, 13, 5604.	1.7	13
846	Clinical evaluation of colony-stimulating factor 1 receptor inhibitors. <i>Seminars in Immunology</i> , 2021, 54, 101514.	2.7	16
847	ARNTL2 is a Prognostic Biomarker and Correlates with Immune Cell Infiltration in Triple-Negative Breast Cancer. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 1425-1440.	0.4	7
848	An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer. <i>BMC Cancer</i> , 2021, 21, 1256.	1.1	12
849	Advanced technologies for single-cell in situ protein profiling. <i>Science China Chemistry</i> , 2022, 65, 48-67.	4.2	8
850	Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2022, 76, 608-618.	1.8	62
851	Decrease in Blood Neutrophil-to-Lymphocyte Ratio Indicates Better Survival After Neoadjuvant Chemotherapy in Patients With Advanced Gastric Cancer. <i>Frontiers in Surgery</i> , 2021, 8, 745748.	0.6	6
852	Vaccines as Priming Tools for T Cell Therapy for Epithelial Cancers. <i>Cancers</i> , 2021, 13, 5819.	1.7	4
853	Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8 ⁺ T _H cells. <i>Cell Reports</i> , 2021, 37, 110013.	2.9	38
854	Identification and clinical validation of EMT-associated prognostic features based on hepatocellular carcinoma. <i>Cancer Cell International</i> , 2021, 21, 621.	1.8	7
855	A Double-Edged Sword Role of Cytokines in Prostate Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 688489.	1.3	11
856	A four immune-related long noncoding RNAs signature as predictors for cervical cancer. <i>Human Cell</i> , 2022, 35, 348-359.	1.2	11
857	Impact of immune cells on the hallmarks of cancer: A literature review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 168, 103541.	2.0	27
858	Novel Pathways for Targeting Tumor Angiogenesis in Metastatic Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 772305.	1.3	18

#	ARTICLE	IF	CITATIONS
859	Prognostic value of JAK3 promoter methylation and mRNA expression in clear cell renal cell carcinoma. <i>Journal of Advanced Research</i> , 2022, 40, 153-166.	4.4	3
860	Proliferating CD8+ T Cell Infiltrates Are Associated with Improved Survival in Glioblastoma. <i>Cells</i> , 2021, 10, 3378.	1.8	24
862	Prognostic value of preoperative neutrophil-to-lymphocyte ratio in histological variants of non-muscle-invasive bladder cancer. <i>Investigative and Clinical Urology</i> , 2021, 62, 641.	1.0	7
863	Immune inactivation by CD47 expression predicts clinical outcomes and therapeutic responses in clear cell renal cell carcinoma patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 166.e15-166.e25.	0.8	6
864	Tertiary lymphoid structures in cancer. <i>Science</i> , 2022, 375, eabf9419.	6.0	303
865	m6A regulator-mediated methylation modification patterns and tumor immune microenvironment in sarcoma. <i>Aging</i> , 2022, 14, 330-353.	1.4	2
866	Accounting for B-cell Behavior and Sampling Bias Predicts Anti-PD-L1 Response in Bladder Cancer. <i>Cancer Immunology Research</i> , 2022, 10, 343-353.	1.6	9
867	Establishment of a Prognostic Prediction and Drug Selection Model for Patients with Clear Cell Renal Cell Carcinoma by Multiomics Data Analysis. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-30.	1.9	6
868	Biomarker-driven immunotherapy for precision medicine in prostate cancer. <i>Personalized Medicine</i> , 2022, 19, 51-66.	0.8	1
871	Polypharmacologic Reprogramming of Tumor-Associated Macrophages toward an Inflammatory Phenotype. <i>Cancer Research</i> , 2022, 82, 433-446.	0.4	6
872	Prognostic Immunophenotyping Clusters of Clear Cell Renal Cell Carcinoma Defined by the Unique Tumor Immune Microenvironment. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 785410.	1.8	12
873	An exploration of immunohistochemistry-based prognostic markers in patients undergoing curative resections for colon cancer. <i>BMC Cancer</i> , 2022, 22, 62.	1.1	5
874	Pyroptosis-Mediated Molecular Subtypes are Characterized by Distinct Tumor Microenvironment Infiltration Characteristics in Breast Cancer. <i>Journal of Inflammation Research</i> , 2022, Volume 15, 345-362.	1.6	9
875	Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 808964.	2.2	53
876	TSH-TSHR axis promotes tumor immune evasion. , 2022, 10, e004049.		16
877	Extracellular matrix-degrading STING nanoagonists for mild NIR-II photothermal-augmented chemodynamic-immunotherapy. <i>Journal of Nanobiotechnology</i> , 2022, 20, 23.	4.2	32
878	Targeting interleukin-1 β and inflammation in lung cancer. <i>Biomarker Research</i> , 2022, 10, 5.	2.8	38
879	Effective CpG Delivery Using Zwitterion-Functionalized Dendrimer-Entrapped Gold Nanoparticles to Promote T Cell-Mediated Immunotherapy of Cancer Cells. <i>Biosensors</i> , 2022, 12, 71.	2.3	4

#	ARTICLE	IF	CITATIONS
880	Prognostic value, DNA variation and immunologic features of a tertiary lymphoid structure-related chemokine signature in clear cell renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1923-1935.	2.0	19
881	Immune inactivation by neuropilin-1 predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2117-2126.	2.0	1
882	Tertiary lymphoid structures and their association to immune phenotypes and circulatory IL2 levels in pancreatic ductal adenocarcinoma. <i>Oncolimmunology</i> , 2022, 11, 2027148.	2.1	11
883	Methylation Pattern Mediated by m6A Regulator and Tumor Microenvironment Invasion in Lung Adenocarcinoma. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-15.	1.9	25
884	A Ferroptosis-Related Gene Prognostic Index to Predict Temozolomide Sensitivity and Immune Checkpoint Inhibitor Response for Glioma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 812422.	1.8	5
885	<sc>PARP</sc> mediated <sc>DNA</sc> damage response, genomic stability and immune responses. <i>International Journal of Cancer</i> , 2022, 150, 1745-1759.	2.3	18
886	T and NK cell abundance defines two distinct subgroups of renal cell carcinoma. <i>Oncolimmunology</i> , 2022, 11, 1993042.	2.1	16
887	IL-1A is associated with postoperative survival and immune contexture in clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, , .	0.8	3
888	Prevalence and Factors Associated with the Loss of PTEN Expression in Patients with Lung Cancer. <i>Siriraj Medical Journal</i> , 2021, 74, 48-63.	0.1	1
889	Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade. <i>Frontiers in Immunology</i> , 2021, 12, 799455.	2.2	76
890	Keep a Little Fire Burningâ€™’The Delicate Balance of Targeting Sphingosine-1-Phosphate in Cancer Immunity. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1289.	1.8	2
891	High IL-23+ cells infiltration correlates with worse clinical outcomes and abiraterone effectiveness in patients with prostate cancer. <i>Asian Journal of Andrology</i> , 2022, 24, 147.	0.8	5
892	Beneficial autoimmunity and maladaptive inflammation shape epidemiological links between cancer and immune-inflammatory diseases. <i>Oncolimmunology</i> , 2022, 11, 2029299.	2.1	4
893	Construction and Comprehensive Prognostic Analysis of a Novel Immune-Related lncRNA Signature and Immune Landscape in Gastric Cancer. <i>International Journal of Genomics</i> , 2022, 2022, 1-23.	0.8	3
894	Comparison of multi-omics results between patients with acute myeloid leukemia with long-term survival and healthy controls. <i>Annals of Translational Medicine</i> , 2022, 10, 82-82.	0.7	1
895	Clinical Significance and Immune Landscape of Recurrence-Associated Ferroptosis Signature in Early-Stage Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 794293.	1.3	0
896	ASF1B: A Possible Prognostic Marker, Therapeutic Target, and Predictor of Immunotherapy in Male Thyroid Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 678025.	1.3	6
897	Identification of Immune Subtypes of Lung Squamous Cell Carcinoma by Integrative Genome-Scale Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 778549.	1.3	2

#	ARTICLE	IF	CITATIONS
898	Intratumoral IL-1R1 expression delineates a distinctive molecular subset with therapeutic resistance in patients with gastric cancer. , 2022, 10, e004047.		12
899	5mC-Related lncRNAs as Potential Prognostic Biomarkers in Colon Adenocarcinoma. <i>Biology</i> , 2022, 11, 231.	1.3	2
900	Ferroptosis-associated molecular classification characterized by distinct tumor microenvironment profiles in colorectal cancer. <i>International Journal of Biological Sciences</i> , 2022, 18, 1773-1794.	2.6	12
901	Classification of early-stage colon cancer with Immunoscore®: clinical evidence and case studies. <i>Future Oncology</i> , 2022, 18, 613-623.	1.1	2
902	Advances in CART-Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment. <i>Frontiers in Immunology</i> , 2022, 13, 830292.	2.2	24
903	Prognosis of Tumor Microenvironment in Luminal B-Type Breast Cancer. <i>Disease Markers</i> , 2022, 2022, 1-21.	0.6	2
904	FOXM1/lncRNA TYMSOS/miR-214-3p Mediated High Expression of NCAPG Correlates With Poor Prognosis and Cell Proliferation in Non-Small Cell Lung Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 785767.	1.6	13
905	DAISM-DNNXMBD: Highly accurate cell type proportion estimation with in silico data augmentation and deep neural networks. <i>Patterns</i> , 2022, 3, 100440.	3.1	10
906	Multi-omics data identified TP53 and LRP1B as key regulatory gene related to immune phenotypes via EPCAM in HCC. <i>Cancer Medicine</i> , 2022, 11, 2145-2158.	1.3	2
907	Radiotherapy resistance: identifying universal biomarkers for various human cancers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1015-1031.	1.2	19
908	Comprehensive analysis of immune cell infiltration and significant genes in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2022, 126, 105755.	0.8	5
909	Recent advance in nanomaterials for cancer immunotherapy. <i>Chemical Engineering Journal</i> , 2022, 435, 134145.	6.6	16
910	Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing. <i>Nature Communications</i> , 2021, 12, 7338.	5.8	104
911	and expression is associated with tumor-infiltrating immune cell abundance and prognosis in clear cell renal cell carcinoma. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 11048-11064.	0.0	0
912	Tumor-Infiltrating Lymphocytes and Their Role in Solid Tumor Progression. <i>Experientia Supplementum (2012)</i> , 2022, 113, 89-106.	0.5	4
913	A Prognostic Model of Colon Cancer Based on the Microenvironment Component Score via Single Cell Sequencing. <i>In Vivo</i> , 2022, 36, 753-763.	0.6	5
914	Multi-Omics Profiling of the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1361, 283-326.	0.8	6
915	CD103+CD8+ tissue-resident memory T cell infiltration predicts clinical outcome and adjuvant therapeutic benefit in muscle-invasive bladder cancer. <i>British Journal of Cancer</i> , 2022, 126, 1581-1588.	2.9	16

#	ARTICLE	IF	CITATIONS
916	Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents. <i>Trends in Cancer</i> , 2022, 8, 426-444.	3.8	13
917	CD105: tumor diagnosis, prognostic marker and future tumor therapeutic target. <i>Clinical and Translational Oncology</i> , 2022, 24, 1447-1458.	1.2	6
918	Gut Microbiota: A Promising Milestone in Enhancing the Efficacy of PD1/PD-L1 Blockade Therapy. <i>Frontiers in Oncology</i> , 2022, 12, 847350.	1.3	6
919	Clinical Significance of Tumor-Infiltrating Conventional and Plasmacytoid Dendritic Cells in Pancreatic Ductal Adenocarcinoma. <i>Cancers</i> , 2022, 14, 1216.	1.7	12
920	Blocking iASPP/Nrf2/M-CSF axis improves anti-cancer effect of chemotherapy-induced senescence by attenuating M2 polarization. <i>Cell Death and Disease</i> , 2022, 13, 166.	2.7	3
921	LncRNA CASC15 upregulates cyclin D1 by downregulating miR-365 in laryngeal squamous cell carcinoma to promote cell proliferation. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , 2022, 51, 8.	0.9	5
922	Immune Contexture and Differentiation Features Predict Outcome in Bladder Cancer. <i>European Urology Oncology</i> , 2022, 5, 203-213.	2.6	14
923	Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors. <i>Nature Communications</i> , 2022, 13, 1487.	5.8	17
924	Apoptotic Body-Mediated Intracellular Delivery Strategy for Enhanced STING Activation and Improved Tumor Immunogenicity. <i>Nano Letters</i> , 2022, 22, 2217-2227.	4.5	18
925	Immunosuppressive tumor-associated macrophages expressing interleukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer. , 2022, 10, e003416.		28
926	Short-Term Fasting Synergizes with Solid Cancer Therapy by Boosting Antitumor Immunity. <i>Cancers</i> , 2022, 14, 1390.	1.7	8
927	A one-dimensional parameter-free model for carcinogenesis in gene expression space. <i>Scientific Reports</i> , 2022, 12, 4748.	1.6	4
928	Lactic Acid Metabolism and Transporter Related Three Genes Predict the Prognosis of Patients with Clear Cell Renal Cell Carcinoma. <i>Genes</i> , 2022, 13, 620.	1.0	5
929	Fibroblast Activation Protein-Alpha is a Prognostic Biomarker Associated With Ferroptosis in Stomach Adenocarcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 859999.	1.8	4
930	Molecular Characterization Clinical and Immunotherapeutic Characteristics of m5C Regulator NOP2 Across 33 Cancer Types. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 839136.	1.8	6
931	Tumor immune cell clustering and its association with survival in African American women with ovarian cancer. <i>PLoS Computational Biology</i> , 2022, 18, e1009900.	1.5	8
932	Patterns of indolence in prostate cancer (Review). <i>Experimental and Therapeutic Medicine</i> , 2022, 23, 351.	0.8	5
933	Immune-related lincRNA pairs predict prognosis and therapeutic response in hepatocellular carcinoma. <i>Scientific Reports</i> , 2022, 12, 4259.	1.6	1

#	ARTICLE	IF	CITATIONS
934	Necroptosis-driving genes <i>RIPK1</i> , <i>RIPK3</i> and <i>MLKL-p</i> are associated with intratumoral CD3 ⁺ and CD8 ⁺ T cell density and predict prognosis in hepatocellular carcinoma. , 2022, 10, e004031.		27
935	Immunosuppressive TREM2(+) macrophages are associated with undesirable prognosis and responses to anti-PD-1 immunotherapy in non-small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2511-2522.	2.0	43
936	Magnetic Resonance Imaging Correlates of Immune Microenvironment in Glioblastoma. <i>Frontiers in Oncology</i> , 2022, 12, 823812.	1.3	5
937	Histone Deacetylase (HDAC) Inhibitors: A Promising Weapon to Tackle Therapy Resistance in Melanoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3660.	1.8	18
938	Immune Landscape and an RBM38-Associated Immune Prognostic Model with Laboratory Verification in Malignant Melanoma. <i>Cancers</i> , 2022, 14, 1590.	1.7	2
939	Irradiation immunity interactions. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2022, 66, 519-535.	0.9	2
940	Deep phenotyping of surface stimulatory and inhibitory co-receptors on cancer-resident T and NK cells reveals cell subsets within the tumor-reactive CTL population that are uniquely defined by NKG2A expression. <i>SLAS Discovery</i> , 2022, 27, 95-106.	1.4	0
941	5-methylcytosine RNA methylation regulators affect prognosis and tumor microenvironment in lung adenocarcinoma. <i>Annals of Translational Medicine</i> , 2022, 10, 259-259.	0.7	15
942	How to Improve SBRT Outcomes in NSCLC: From Pre-Clinical Modeling to Successful Clinical Translation. <i>Cancers</i> , 2022, 14, 1705.	1.7	4
943	Prognostic Significance of Neutrophil-to-Lymphocyte Ratio and C-Reactive Protein/Albumin Ratio in Luminal Breast Cancers With HER2-Negativity. <i>Frontiers in Oncology</i> , 2022, 12, 845935.	1.3	4
944	Single-Cell RNA-seq Reveals a Developmental Hierarchy Superimposed Over Subclonal Evolution in the Cellular Ecosystem of Prostate Cancer. <i>Advanced Science</i> , 2022, 9, e2105530.	5.6	14
945	Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 132.	3.5	21
946	The Prognostic Signature of Head and Neck Squamous Cell Carcinoma Constructed by Immune-Related RNA-Binding Proteins. <i>Frontiers in Oncology</i> , 2022, 12, 795781.	1.3	6
947	All is not lost: learning from 9p21 loss in cancer. <i>Trends in Immunology</i> , 2022, 43, 379-390.	2.9	12
948	Cross-reactivity between microbial and tumor antigens. <i>Current Opinion in Immunology</i> , 2022, 75, 102171.	2.4	16
949	Engineering strategies to enhance oncolytic viruses in cancer immunotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 117.	7.1	72
950	B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 441-457.	12.5	176
951	Macrophage and T-Cell Infiltration and Topographic Immune Cell Distribution in Non-Melanoma Skin Cancer of the Head and Neck. <i>Frontiers in Oncology</i> , 2022, 12, 809687.	1.3	0

#	ARTICLE	IF	CITATIONS
952	Two sides of the same coin: Protective versus pathogenic CD4 ⁺ resident memory T cells. <i>Science Immunology</i> , 2022, 7, eabf9393.	5.6	11
953	Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types. <i>Journal of Pathology: Clinical Research</i> , 2022, 8, 371-382.	1.3	10
954	Nanodrug shows spatiotemporally controlled release of anti-PD-L1 antibody and STING agonist to effectively inhibit tumor progression after radiofrequency ablation. <i>Nano Today</i> , 2022, 43, 101425.	6.2	15
955	Imaging and therapeutic targeting of the tumor immune microenvironment with biologics. <i>Advanced Drug Delivery Reviews</i> , 2022, 184, 114239.	6.6	7
956	The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features. <i>Cancer Treatment Reviews</i> , 2022, 106, 102382.	3.4	9
957	cGAS-STING signalings potentiate tumor progression via sustaining cancer stemness. <i>Translational Oncology</i> , 2022, 20, 101404.	1.7	7
958	Prognostic Significance of NLR About NETosis and Lymphocytes Perturbations in Localized Renal Cell Carcinoma With Tumor Thrombus. <i>Frontiers in Oncology</i> , 2021, 11, 771545.	1.3	10
959	A Nomogram Based on Circulating CD4 ⁺ T Lymphocytes and Lactate Dehydrogenase to Predict Distant Metastasis in Patients with Nasopharyngeal Carcinoma. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 6707-6718.	1.6	5
960	The pattern of alternative splicing in lung adenocarcinoma shows novel events correlated with tumorigenesis and immune microenvironment. <i>BMC Pulmonary Medicine</i> , 2021, 21, 400.	0.8	0
961	CD248 ⁺ Cancer-Associated Fibroblasts: A Novel Prognostic and Therapeutic Target for Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 773063.	1.3	9
962	Bulk and Single-Cell Profiling of Breast Tumors Identifies TREM-1 as a Dominant Immune Suppressive Marker Associated With Poor Outcomes. <i>Frontiers in Oncology</i> , 2021, 11, 734959.	1.3	8
963	A Novel Model of Tumor-Infiltrating B Lymphocyte Specific RNA-Binding Protein-Related Genes With Potential Prognostic Value and Therapeutic Targets in Multiple Myeloma. <i>Frontiers in Genetics</i> , 2021, 12, 778715.	1.1	0
964	SEMA6B Overexpression Predicts Poor Prognosis and Correlates With the Tumor Immunosuppressive Microenvironment in Colorectal Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 687319.	1.6	10
965	Toll-Like Receptors (TLRs), NOD-Like Receptors (NLRs), and RIG-I-Like Receptors (RLRs) in Innate Immunity. TLRs, NLRs, and RLRs Ligands as Immunotherapeutic Agents for Hematopoietic Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13397.	1.8	77
966	Identification and Validation of Hub Genes Associated with Bladder Cancer by Integrated Bioinformatics and Experimental Assays. <i>Frontiers in Oncology</i> , 2021, 11, 782981.	1.3	11
967	Reduced Interleukin-17-Expressing Cells in Cutaneous Melanoma. <i>Biomedicines</i> , 2021, 9, 1930.	1.4	2
968	T cells in pancreatic cancer stroma. <i>World Journal of Gastroenterology</i> , 2021, 27, 7956-7968.	1.4	26
969	Macrophages-based immune-related risk score model for relapse prediction in stage III non-small cell lung cancer assessed by multiplex immunofluorescence. <i>Translational Lung Cancer Research</i> , 2022, 11, 523-542.	1.3	8

#	ARTICLE	IF	CITATIONS
970	A 25 Immune-Related Gene Pair Signature Predicts Overall Survival in Cervical Cancer. <i>Cancer Informatics</i> , 2022, 21, 117693512210909.	0.9	1
971	Understanding Drug Sensitivity and Tackling Resistance in Cancer. <i>Cancer Research</i> , 2022, 82, 1448-1460.	0.4	24
972	STING and TLR7/8 agonists-based nanovaccines for synergistic antitumor immune activation. <i>Nano Research</i> , 2022, 15, 6328-6339.	5.8	13
973	m6A Methylation Patterns and Tumor Microenvironment Infiltration Characterization in Clear-Cell Renal Cell Carcinoma. <i>Frontiers in Genetics</i> , 2022, 13, 864549.	1.1	5
974	Single-Cell Sequencing Identifies the Heterogeneity of CD8+ T Cells and Novel Biomarker Genes in Hepatocellular Carcinoma. <i>Journal of Healthcare Engineering</i> , 2022, 2022, 1-16.	1.1	7
975	Integrated immunogenomic analysis of single-cell and bulk tissue transcriptome profiling unravels a macrophage activation paradigm associated with immunologically and clinically distinct behaviors in ovarian cancer. <i>Journal of Advanced Research</i> , 2023, 44, 149-160.	4.4	8
976	Comprehensive analysis of ZFPM2-AS1 prognostic value, immune microenvironment, drug sensitivity, and co-expression network: from gastric adenocarcinoma to pan-cancers. <i>Discover Oncology</i> , 2022, 13, 24.	0.8	3
1074	Coupling the immunomodulatory properties of the HDAC6 inhibitor ACY241 with Oxaliplatin promotes robust anti-tumor response in non-small cell lung cancer. <i>Oncolmmunology</i> , 2022, 11, 2042065.	2.1	8
1076	dNLR and TILS can be used as indicators for prognosis and efficacy evaluation of neo-adjuvant chemotherapy in breast cancer.. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 13093-13098.	0.0	0
1077	Spatial analysis and CD25-expression identify regulatory T cells as predictors of a poor prognosis in colorectal cancer. <i>Modern Pathology</i> , 2022, 35, 1236-1246.	2.9	8
1078	Tumor Microenvironment Characterization for Assessment of Recurrence and Survival Outcome in Gastric Cancer to Predict Chemotherapy and Immunotherapy Response. <i>Frontiers in Immunology</i> , 2022, 13, 890922.	2.2	6
1079	Characterizing the Inflammatory Microenvironment in K14-HPV16 Transgenic Mice: Mast Cell Infiltration and MicroRNA Expression. <i>Cancers</i> , 2022, 14, 2216.	1.7	4
1080	Chronic Cancer Pain: Opioids within Tumor Microenvironment Affect Neuroinflammation, Tumor and Pain Evolution. <i>Cancers</i> , 2022, 14, 2253.	1.7	17
1081	Non-Coding RNAs Implicated in the Tumor Microenvironment of Colorectal Cancer: Roles, Mechanisms and Clinical Study. <i>Frontiers in Oncology</i> , 2022, 12, 888276.	1.3	1
1082	A Novel Immune-Prognosis Index Predicts the Benefit of Lung Adenocarcinoma Patients. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	1
1083	Role of Metabolism in Adoptive T Cell Therapy: Strategies and Challenges. <i>Antioxidants and Redox Signaling</i> , 2022, 37, 1303-1324.	2.5	1
1084	Immune effects of CDK4/6 inhibitors in patients with HR+/HER2 ⁺ metastatic breast cancer: Relief from immunosuppression is associated with clinical response. <i>EBioMedicine</i> , 2022, 79, 104010.	2.7	22
1085	CD20+CD22+ADAM28+ B Cells in Tertiary Lymphoid Structures Promote Immunotherapy Response. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	8

#	ARTICLE	IF	CITATIONS
1086	An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 3053-3065.	3.2	26
1087	Multi-Omics Analyses to Identify FCGBP as a Potential Predictor in Head and Neck Squamous Cell Carcinoma. <i>Diagnostics</i> , 2022, 12, 1178.	1.3	1
1088	CXCL13-producing CD4+ T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer. <i>JCI Insight</i> , 2022, 7, .	2.3	48
1089	NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer. , 2022, 10, e004569.		5
1091	Kidney Cancer Models for Pre-Clinical Drug Discovery: Challenges and Opportunities. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	2
1092	Radionuclide Imaging of Cytotoxic Immune Cell Responses to Anti-Cancer Immunotherapy. <i>Biomedicines</i> , 2022, 10, 1074.	1.4	3
1093	Sestrin2 in cancer: a foe or a friend?. <i>Biomarker Research</i> , 2022, 10, 29.	2.8	2
1094	High-throughput single-Cell sequencing in cancer research. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 145.	7.1	39
1095	Detection of Specific Immune Cell Subpopulation Changes Associated with Systemic Immune Inflammationâ€“Index Level in Germ Cell Tumors. <i>Life</i> , 2022, 12, 678.	1.1	1
1096	Different In Situ Immune Patterns between Primary Tumor and Lymph Node in Non-Small-Cell Lung Cancer: Potential Impact on Neoadjuvant Immunotherapy. <i>Journal of Immunology Research</i> , 2022, 2022, 1-14.	0.9	2
1097	Amino Acid Metabolism-Related lncRNA Signature Predicts the Prognosis of Breast Cancer. <i>Frontiers in Genetics</i> , 2022, 13, .	1.1	9
1098	Breaking the Immune Complexity of the Tumor Microenvironment Using Single-Cell Technologies. <i>Frontiers in Genetics</i> , 2022, 13, .	1.1	3
1099	A topology perspective on macrophages in melanoma metastasis. <i>Cell Reports Medicine</i> , 2022, 3, 100643.	3.3	0
1100	Identifying tumor antigens and immunoâ€“subtyping in colon adenocarcinoma to facilitate the development of <scp>mRNA</scp> vaccine. <i>Cancer Medicine</i> , 2022, , .	1.3	3
1101	Bulk and single-cell transcriptome profiling reveal necroptosis-based molecular classification, tumor microenvironment infiltration characterization, and prognosis prediction in colorectal cancer. <i>Journal of Translational Medicine</i> , 2022, 20, 235.	1.8	7
1102	Real-world data on the efficacy and safety of pazopanib in IMDC favorable- and intermediate-risk metastatic renal cell carcinoma: a multicenter retrospective cohort study of Chinese patients. <i>Translational Andrology and Urology</i> , 2022, 11, 694-709.	0.6	2
1103	Single cell analysis reveals intraâ€“tumour heterogeneity, microenvironment and potential diagnosis markers for clear cell renal cell carcinoma. <i>Clinical and Translational Medicine</i> , 2022, 12, .	1.7	4
1104	Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Current Progresses and Challenges. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 955-964.	0.7	9

#	ARTICLE	IF	CITATIONS
1105	Anti-tumor and immunomodulation activity of polysaccharides from <i>Dendrobium officinale</i> in S180 tumor-bearing mice. <i>Journal of Functional Foods</i> , 2022, 94, 105105.	1.6	10
1106	A comprehensive profiling of the immune microenvironment of breast cancer brain metastases. <i>Neuro-Oncology</i> , 2022, 24, 2146-2158.	0.6	9
1107	Identification of Senescence-Related Subtypes, the Development of a Prognosis Model, and Characterization of Immune Infiltration and Gut Microbiota in Colorectal Cancer. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	5
1108	Inhibition of autolysosomes by repurposing drugs as a promising therapeutic strategy for the treatment of cancers. <i>International Journal of Transgender Health</i> , 2022, 15, 568-601.	1.1	2
1109	Emerging Roles of Immune Cells in Cancer Development and Progression. <i>Cancers</i> , 2022, 14, 2642.	1.7	0
1111	Plasma profile of immune determinants predicts pathological complete response in locally advanced breast cancer patients: a pilot study. <i>Clinical Breast Cancer</i> , 2022, , .	1.1	0
1112	Decoding Lung Cancer at Single-Cell Level. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	4
1113	N6-methyladenosine methylation modification patterns reveal immune profiling in pancreatic adenocarcinoma. <i>Cancer Cell International</i> , 2022, 22, .	1.8	7
1114	Probiotic <i>Lactobacillus brevis</i> CLB3 prevents azoxymethane/dextran sulfate sodium induced colon carcinogenesis in mice by reducing amino acid transport and IL-17A levels and repressing the IL-6/AKT/p-STAT3 signaling pathway. <i>Food Quality and Safety</i> , 0, , .	0.6	0
1115	Lack of Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in Early Breast Cancer. <i>Breast Care</i> , 2022, 17, 546-553.	0.8	0
1116	Identification of Ligand-Receptor Pairs Associated With Tumour Characteristics in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	10
1117	Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer. , 2022, 10, e004440.		49
1118	Pathological Response and Immune Biomarker Assessment in Non-Small-Cell Lung Carcinoma Receiving Neoadjuvant Immune Checkpoint Inhibitors. <i>Cancers</i> , 2022, 14, 2775.	1.7	5
1119	Hypoxia-driven metabolic heterogeneity and immune evasive behaviour of gastrointestinal cancers: Elements of a recipe for disaster. <i>Cytokine</i> , 2022, 156, 155917.	1.4	1
1121	A single-sample mRNA molecular classification of bladder cancer predicting prognosis and response to immunotherapy. <i>Translational Andrology and Urology</i> , 2021, .	0.6	0
1122	Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 3106-3119.	1.9	17
1123	Weighted Gene Co-Expression Network Analysis (WGCNA) Reveals the Functions of Syndecan-1 to Regulate Immune Infiltration by Influenced T Cells in Glioma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
1124	Targeting the Tumor Microenvironment in Acute Myeloid Leukemia: The Future of Immunotherapy and Natural Products. <i>Biomedicines</i> , 2022, 10, 1410.	1.4	4

#	ARTICLE	IF	CITATIONS
1125	Virus-Based Immuno-Oncology Models. <i>Biomedicines</i> , 2022, 10, 1441.	1.4	4
1126	Tumor pH-Responsive Nanocarriers With Light-Activatable Drug Release for Chemo-Photodynamic Therapy of Breast Cancer. <i>Frontiers in Chemistry</i> , 0, 10, .	1.8	1
1127	Association Between CD204-Expressed Tumor-Associated Macrophages and <i>MGMT</i> -Promoter Methylation in the Microenvironment of Grade 4 Astrocytomas. <i>World Journal of Oncology</i> , 2022, 13, 117-125.	0.6	4
1128	Tertiary lymphoid structures favor outcome in resected esophageal squamous cell carcinoma. <i>Journal of Pathology: Clinical Research</i> , 2022, 8, 422-435.	1.3	8
1129	Nanoparticles mediated tumor microenvironment modulation: current advances and applications. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	4.2	24
1130	Tracking circulating tumour-associated T cells for the early diagnosis of cancer. <i>Clinical and Translational Discovery</i> , 2022, 2, .	0.2	0
1131	Context-Dependent Effects Explain Divergent Prognostic Roles of Tregs in Cancer. <i>Cancers</i> , 2022, 14, 2991.	1.7	2
1132	KDM5A Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in Ovarian Cancer. <i>Cancer Immunology Research</i> , 2022, 10, 1028-1038.	1.6	6
1133	RT-PCR-assisted quantification of type I IFN responses in irradiated cancer cells. <i>Methods in Cell Biology</i> , 2022, , .	0.5	0
1134	Identification and verification of immune-related gene prognostic signature based on ssGSEA for breast cancer. <i>Central-European Journal of Immunology</i> , 2022, 47, 139-150.	0.4	1
1135	Novel Pyroptosis-Related Gene Signatures Identified as the Prognostic Biomarkers for Bladder Carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
1136	Analysis of ARHGAP4 Expression With Colorectal Cancer Clinical Characteristics and Prognosis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
1137	Cancer cell-autonomous overactivation of PARP1 compromises immunosurveillance in non-small cell lung cancer. , 2022, 10, e004280.		7
1138	A single-cell map of dynamic chromatin landscapes of immune cells in renal cell carcinoma. <i>Nature Cancer</i> , 2022, 3, 885-898.	5.7	20
1139	Oncolytic immunotherapy: multiple mechanisms of oncolytic peptides to confer anticancer immunity. , 2022, 10, e005065.		6
1140	Identification of Survival Risk and Immune-Related Characteristics of Kidney Renal Clear Cell Carcinoma. <i>Journal of Immunology Research</i> , 2022, 2022, 1-37.	0.9	4
1141	The unique genomic landscape and prognostic mutational signature of Chinese clear cell renal cell carcinoma. <i>Journal of the National Cancer Center</i> , 2022, 2, 162-170.	3.0	7
1142	Prognostic value of tumor immune biomarkers in biopsies from patients with refractory solid cancers. <i>Cancer Treatment and Research Communications</i> , 2022, 32, 100611.	0.7	0

#	ARTICLE	IF	CITATIONS
1143	Stromal or intraepithelial tumor-infiltrating lymphocytes: which one has more prognostic significance in cervical cancer?. Archives of Gynecology and Obstetrics, 2023, 307, 969-980.	0.8	3
1144	Complement activation in cancer: Effects on tumor-associated myeloid cells and immunosuppression. Seminars in Immunology, 2022, 60, 101642.	2.7	9
1145	Identification of Grb2-associated binding protein 3 expression to predict clinical outcomes and immunotherapeutic responses in lung adenocarcinoma. Journal of Biochemical and Molecular Toxicology, 2022, 36, .	1.4	2
1146	Stromal and Immune Cell Dynamics in Tumor Associated Tertiary Lymphoid Structures and Anti-Tumor Immune Responses. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	3
1147	Cancer Biology and Implications for the Perioperative Period. , 2023, , 24-45.		1
1148	The Role of Tumor Microenvironment and Immune Response in Colorectal Cancer Development and Prognosis. Pathology and Oncology Research, 0, 28, .	0.9	9
1149	Host <sc>STING</sc> is essential for the efficacy of <sc>anti-PD</sc> -1 inhibitors in non-small cell lung cancer. Immunology, 0, , .	2.0	1
1150	CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment. Frontiers in Immunology, 0, 13, .	2.2	6
1151	m6A Regulator-Based Methylation Modification Patterns Characterized by Distinct Tumor Microenvironment Immune Profiles in Rectal Cancer. Frontiers in Oncology, 0, 12, .	1.3	1
1152	Intratumoral spatial heterogeneity of tumor-infiltrating lymphocytes is a significant factor for precisely stratifying prognostic immune subgroups of microsatellite instability-high colorectal carcinomas. Modern Pathology, 2022, 35, 2011-2022.	2.9	10
1153	Tumor-infiltrating lymphocytes predict survival in pT2 urothelial bladder cancer. Pathology Research and Practice, 2022, 237, 154037.	1.0	3
1154	Novel Biomarkers in Lung Cancer and Chronic Lung Diseases: From the Systematic Perspective of Yin-Yang Balance. Journal of Clinical Medicine, 2022, 11, 4275.	1.0	0
1155	Dynamic CD8+ T Cell Cooperation with Macrophages and Monocytes for Successful Cancer Immunotherapy. Cancers, 2022, 14, 3546.	1.7	8
1156	8-Gene signature related to CD8+ T cell infiltration by integrating single-cell and bulk RNA-sequencing in head and neck squamous cell carcinoma. Frontiers in Genetics, 0, 13, .	1.1	5
1157	How Chemotherapy Affects the Tumor Immune Microenvironment: A Narrative Review. Biomedicines, 2022, 10, 1822.	1.4	11
1158	Immune-Related Biomarkers Improve Performance of Risk Prediction Models for Survival in Patients With Hepatocellular Carcinoma. Frontiers in Oncology, 0, 12, .	1.3	0
1159	An immune-related gene prognostic risk index for pancreatic adenocarcinoma. Frontiers in Immunology, 0, 13, .	2.2	1
1160	Acute and Chronic Effects of Adjuvant Therapy on Inflammatory Markers in Breast Cancer Patients. JNCI Cancer Spectrum, 2022, 6, .	1.4	8

#	ARTICLE	IF	CITATIONS
1161	Crosstalk of three novel types of programmed cell death defines distinct microenvironment characterization and pharmacogenomic landscape in breast cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1162	<sc>DKK1</sc> drives immune suppressive phenotypes in intrahepatic cholangiocarcinoma and can be targeted with <sc>anti-â€œDKK1</sc> therapeutic <sc>DKN</sc>â€œ01. <i>Liver International</i> , 2023, 43, 208-220.	1.9	7
1163	Identification of the pyroptosis-related prognostic gene signature and characterization of tumor microenvironment infiltration in triple-negative breast cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
1164	Intratumoral PD-1+CD8+ T cells associate poor clinical outcomes and adjuvant chemotherapeutic benefit in gastric cancer. <i>British Journal of Cancer</i> , 2022, 127, 1709-1717.	2.9	13
1166	A score of DNA damage repair pathway with the predictive ability for chemotherapy and immunotherapy is strongly associated with immune signaling pathway in pan-cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
1167	Identification of Candidate Therapeutic Target Genes and Profiling of Tumor-Infiltrating Immune Cells in Pancreatic Cancer via Integrated Transcriptomic Analysis. <i>Disease Markers</i> , 2022, 2022, 1-14.	0.6	1
1168	Microraft arrays for <sc>serial-killer CD19</sc> chimeric antigen receptor T cells and single cell isolation. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2023, 103, 208-220.	1.1	2
1169	A Paradoxical Role for Regulatory T Cells in the Tumor Microenvironment of Pancreatic Cancer. <i>Cancers</i> , 2022, 14, 3862.	1.7	8
1170	MTUS1 is a promising diagnostic and prognostic biomarker for colorectal cancer. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	4
1171	Identification of the Tumor Infiltrating Lymphocytes (TILs) Landscape in Pure Squamous Cell Carcinoma of the Bladder. <i>Cancers</i> , 2022, 14, 3999.	1.7	2
1172	Pan-cancer integrative histology-genomic analysis via multimodal deep learning. <i>Cancer Cell</i> , 2022, 40, 865-878.e6.	7.7	109
1173	Based on clinical Ki-67 expression and serum infiltrating lymphocytes related nomogram for predicting the diagnosis of glioma-grading. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1174	Anti-PD-1/PD-L1 immunotherapy in conversion treatment of locally advanced hepatocellular carcinoma. <i>Clinical and Experimental Medicine</i> , 2023, 23, 579-590.	1.9	6
1175	m6A regulator-mediated methylation modification highlights immune infiltration patterns for predicting risk in hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	0
1176	The HPV Induced Cancer Resource (THInCR): a Suite of Tools for Investigating HPV-Dependent Human Carcinogenesis. <i>MSphere</i> , 2022, 7, .	1.3	5
1177	A novel chemokine-â€œbased signature for prediction of prognosis and therapeutic response in glioma. <i>CNS Neuroscience and Therapeutics</i> , 2022, 28, 2090-2103.	1.9	9
1178	Immuno-genomic profiling of biopsy specimens predicts neoadjuvant chemotherapy response in esophageal squamous cell carcinoma. <i>Cell Reports Medicine</i> , 2022, 3, 100705.	3.3	5
1179	Prognostic and Immunological Significance of FUNDC1 in Hepatocellular Carcinoma: A Study on TCGA Mining. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-15.	0.7	3

#	ARTICLE	IF	CITATIONS
1181	Identification of Cytosolic DNA Sensor cGAS-STING as Immune-Related Risk Factor in Renal Carcinoma following Pan-Cancer Analysis. <i>Journal of Immunology Research</i> , 2022, 2022, 1-11.	0.9	2
1182	HAMP as a Prognostic Biomarker for Colorectal Cancer Based on Tumor Microenvironment Analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
1183	Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas. <i>Blood</i> , 2022, 140, 1951-1963.	0.6	9
1184	Integrated risk scores from N6-methyladenosine-related lncRNAs are potential biomarkers for predicting the overall survival of bladder cancer patients. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
1185	Immune features of the peritumoral stroma in pancreatic ductal adenocarcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1186	CD200 ectodomain shedding into the tumor microenvironment leads to NK cell dysfunction and apoptosis. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	13
1187	Adenosine A2a Receptor Antagonism Restores Additive Cytotoxicity by Cytotoxic T Cells in Metabolically Perturbed Tumors. <i>Cancer Immunology Research</i> , 2022, 10, 1462-1474.	1.6	5
1188	The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	21
1189	Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
1190	A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma. <i>Clinical Cancer Research</i> , 2022, 28, 5058-5065.	3.2	6
1191	Identification of ST3GAL5 as a prognostic biomarker correlating with CD8+ T cell exhaustion in clear cell renal cell carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
1192	DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma. <i>Cancer Letters</i> , 2022, 548, 215899.	3.2	18
1193	Decoding the associations between cell functional states in head and neck cancer based on single-cell transcriptome. <i>Oral Oncology</i> , 2022, 134, 106110.	0.8	1
1194	A double-edged sword: The HBV-induced non-coding RNAs alterations in hepatocellular carcinoma. <i>Biocell</i> , 2023, 47, 27-32.	0.4	0
1195	Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness. <i>Theranostics</i> , 2022, 12, 6106-6129.	4.6	14
1196	Family with sequence similarity 153 member B as a potential prognostic biomarker of gastric cancer. <i>Mathematical Biosciences and Engineering</i> , 2022, 19, 12581-12600.	1.0	0
1197	Synthetic-Based Tumor-Infiltrating Lymphocytes (TILs) in Adoptive Cell Therapies. , 2022, , 1-27.		0
1198	Cancer prognosis and immune system. , 2022, , 75-144.		0

#	ARTICLE	IF	CITATIONS
1199	Tumor-associated macrophage-derived chemokine CCL5 facilitates the progression and immunosuppressive tumor microenvironment of clear cell renal cell carcinoma. <i>International Journal of Biological Sciences</i> , 2022, 18, 4884-4900.	2.6	22
1200	Role of Tumor-associated neutrophils in the breast tumor microenvironment. , 2022, , 171-194.		0
1201	Integrated analysis and validation reveal ACAP1 as a novel prognostic biomarker associated with tumor immunity in lung adenocarcinoma. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 4390-4401.	1.9	2
1202	Prognostic value of neutrophil-to-lymphocyte ratio for patients with triple-negative breast cancer: A meta-analysis. <i>Medicine (United States)</i> , 2022, 101, e29887.	0.4	4
1203	The Ferroptosis Molecular Subtype Reveals Characteristics of the Tumor Microenvironment, Immunotherapeutic Response, and Prognosis in Gastric Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9767.	1.8	2
1204	Pan-Cancer Analysis Reveals the Relation between TRMT112 and Tumor Microenvironment. <i>Journal of Oncology</i> , 2022, 2022, 1-11.	0.6	4
1205	Pyroptosis-Related Gene Model Predicts Prognosis and Immune Microenvironment for Non-Small-Cell Lung Cancer. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-27.	1.9	3
1206	Noninvasive imaging of the tumor immune microenvironment correlates with response to immunotherapy in gastric cancer. <i>Nature Communications</i> , 2022, 13, .	5.8	25
1207	Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide-Based Vaccine in Patients With Refractory Advanced Non-Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study. <i>Journal of Clinical Oncology</i> , 2023, 41, 373-384.	0.8	11
1208	The cuproptosis-associated 13 gene signature as a robust predictor for outcome and response to immune- and targeted-therapies in clear cell renal cell carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	20
1209	Targeting tumour-reprogrammed myeloid cells: the new battleground in cancer immunotherapy. <i>Seminars in Immunopathology</i> , 2023, 45, 163-186.	2.8	14
1210	VISTA is associated with immune infiltration and predicts favorable prognosis in TNBC. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
1211	The expression pattern of immune-related genes and characterization of tumor immune microenvironment: predicting prognosis and immunotherapeutic effects in cutaneous melanoma. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	1
1212	Integrated TCR repertoire analysis and single-cell transcriptomic profiling of tumor-infiltrating T cells in renal cell carcinoma identifies shared and tumor-restricted expanded clones with unique phenotypes. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1213	Simultaneous Expression of PD-1 and PD-L1 in Peripheral and Central Immune Cells and Tumor Cells in the Benign and Malignant Salivary Gland Tumors Microenvironment. <i>Head and Neck Pathology</i> , 2023, 17, 178-192.	1.3	7
1214	Pancreatic ductal adenocarcinoma: tumor microenvironment and problems in the development of novel therapeutic strategies. <i>Clinical and Experimental Medicine</i> , 2023, 23, 619-643.	1.9	7
1215	Mass cytometry-based peripheral blood analysis as a novel tool for early detection of solid tumours: a multicentre study. <i>Gut</i> , 2023, 72, 996-1006.	6.1	4
1216	Intratumoral CD73: An immune checkpoint shaping an inhibitory tumor microenvironment and implicating poor prognosis in Chinese melanoma cohorts. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8

#	ARTICLE	IF	CITATIONS
1217	Development and verification of an immune-related gene prognostic index for gastric cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
1218	A vicious circle in breast cancer: The interplay between inflammation, reactive oxygen species, and microRNAs. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
1219	Editorial: Tumor microenvironment signaling networks in pathophysiology and therapeutics. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1220	Tumor Microenvironment CD14+ Cells Correlate with Poor Overall Survival in Patients with Early-Stage Lung Adenocarcinoma. <i>Cancers</i> , 2022, 14, 4501.	1.7	1
1221	The Immune Contexture of Liposarcoma and Its Clinical Implications. <i>Cancers</i> , 2022, 14, 4578.	1.7	6
1222	Epithelial PD-1 expression at tumor front predicts overall survival in a cohort of oral squamous cell carcinomas from Sudan. <i>Clinical and Experimental Dental Research</i> , 0, , .	0.8	1
1223	m7G regulator-mediated molecular subtypes and tumor microenvironment in kidney renal clear cell carcinoma. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
1224	Nanoparticle-Based Drug Delivery Systems Targeting Tumor Microenvironment for Cancer Immunotherapy Resistance: Current Advances and Applications. <i>Pharmaceutics</i> , 2022, 14, 1990.	2.0	17
1225	In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response. <i>Nature Communications</i> , 2022, 13, .	5.8	15
1226	Construction of a tumor immune infiltration macrophage signature for predicting prognosis and immunotherapy response in liver cancer. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	1
1227	A multi-omics-based investigation of the prognostic and immunological impact of necroptosis-related mRNA in patients with cervical squamous carcinoma and adenocarcinoma. <i>Scientific Reports</i> , 2022, 12, .	1.6	10
1228	The T Cell Journey: A Tour de Force. <i>Advanced Biology</i> , 2023, 7, .	1.4	4
1229	Immunotherapies catering to the unmet medical need of cold colorectal cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
1230	Chemotherapy-induced complement signaling modulates immunosuppression and metastatic relapse in breast cancer. <i>Nature Communications</i> , 2022, 13, .	5.8	41
1232	BATF epigenetically and transcriptionally controls the activation program of regulatory T cells in human tumors. <i>Science Immunology</i> , 2022, 7, .	5.6	23
1233	Development of cancer-associated fibroblasts subtype and prognostic model in gastric cancer and the landscape of tumor microenvironment. <i>International Journal of Biochemistry and Cell Biology</i> , 2022, 152, 106309.	1.2	2
1234	Cancer Immunotherapy Clinical Trials. , 2022, , 1-24.		0
1235	Lipid-mediated delivery of CD47 siRNA aids JQ1 in ensuring simultaneous downregulation of PD-L1 and CD47 and improves antitumor immunotherapy efficacy. <i>Biomaterials Science</i> , 2022, 10, 6755-6767.	2.6	3

#	ARTICLE	IF	CITATIONS
1236	Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genes. , 2022, 10, e003744.		6
1237	CD45RO+TILs: cellular biomarkers for larynx squamous cell carcinoma outcome. Brazilian Journal of Otorhinolaryngology, 2022, 88, S133-S142.	0.4	1
1238	Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced nonâ€small cell lung cancer: A multiplex immunohistochemistryâ€based single-cell analysis. Lung Cancer, 2022, 174, 71-82.	0.9	3
1239	Inflammation-related parameter serve as prognostic biomarker in esophageal squamous cell carcinoma. Frontiers in Oncology, 0, 12, .	1.3	3
1240	Single-Molecular Methodologies for the Physical Biology of Protein Machines. Chinese Physics B, 0, , .	0.7	1
1241	Application of nanomaterials in combined thermal ablation and immunotherapy for liver tumors. World Chinese Journal of Digestology, 2022, 30, 829-837.	0.0	0
1242	Dendritic Cells or Macrophages? The Microenvironment of Human Clear Cell Renal Cell Carcinoma Imprints a Mosaic Myeloid Subtype Associated with Patient Survival. Cells, 2022, 11, 3289.	1.8	2
1243	A CD8+ T cell-associated immune gene panel for prediction of the prognosis and immunotherapeutic effect of melanoma. Frontiers in Immunology, 0, 13, .	2.2	3
1245	Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance. Frontiers in Oncology, 0, 12, .	1.3	8
1246	Cellular milieu in clear cell renal cell carcinoma. Frontiers in Oncology, 0, 12, .	1.3	5
1247	Wnt Signaling in the Phenotype and Function of Tumor-Associated Macrophages. Cancer Research, 2023, 83, 3-11.	0.4	4
1248	CD8A as a Prognostic and Immunotherapy Predictive Biomarker Can Be Evaluated by MRI Radiomics Features in Bladder Cancer. Cancers, 2022, 14, 4866.	1.7	13
1249	Tertiary lymphoid structures associate with improved survival in early oral tongue cancer. BMC Cancer, 2022, 22, .	1.1	3
1250	Biological and Therapeutic Implications of the Tumor Microenvironment in Pituitary Adenomas. Endocrine Reviews, 2023, 44, 297-311.	8.9	13
1251	An ion-channel-gene-based prediction model for head and neck squamous cell carcinoma: Prognostic assessment and treatment guidance. Frontiers in Immunology, 0, 13, .	2.2	4
1252	NK cells and solid tumors: therapeutic potential and persisting obstacles. Molecular Cancer, 2022, 21, .	7.9	42
1253	Deconvolution of bulk tumors into distinct immune cell states predicts colorectal cancer recurrence. IScience, 2022, 25, 105392.	1.9	2
1254	Interdependence of sequential cytotoxic T lymphocyte and natural killer cell cytotoxicity against melanoma cells. Journal of Physiology, 2022, 600, 5027-5054.	1.3	5

#	ARTICLE	IF	CITATIONS
1255	Understanding the Immunoenvironment of Primary Liver Cancer: A Histopathology Perspective. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 1149-1169.	1.8	3
1256	A novel ten-gene prognostic signature for cervical cancer based on CD79B-related immunomodulators. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
1257	High endothelial venules associated with better prognosis in esophageal squamous cell carcinoma. <i>Annals of Diagnostic Pathology</i> , 2022, 61, 152051.	0.6	2
1258	The thin red line between the immune system and cancer evolution. <i>Translational Oncology</i> , 2023, 27, 101555.	1.7	1
1259	Immunological Effects of Conventional Anticancer Drugs. , 2022, , 1-13.		0
1260	Making Rituximab Directly Cytotoxic for Substantial Improvement in Therapeutic Efficacy. <i>European Medical Journal Hematology</i> , 0, , 82-90.	0.0	0
1261	Novel peripheral blood parameters as predictors of neoadjuvant chemotherapy response in breast cancer. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	3
1262	CX3CL1 promotes cell sensitivity to ferroptosis and is associated with the tumor microenvironment in clear cell renal cell carcinoma. <i>BMC Cancer</i> , 2022, 22, .	1.1	6
1263	A novel immune signature predicts immunotherapy responsiveness and reveals the landscape of the tumor immune microenvironment in head and neck squamous cell carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
1264	Murine neonatal dermal fibroblast acquires a lymphoid tissue organizer cell-like activity upon synergistic activation of TNF- β receptor and LT β receptor. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2023, 1870, 119399.	1.9	0
1265	Identification of novel prognostic and predictive biomarkers in salivary duct carcinoma via comprehensive molecular profiling. <i>Npj Precision Oncology</i> , 2022, 6, .	2.3	4
1266	Transcriptomic characterization and construction of M2 macrophage-related prognostic and immunotherapeutic signature in ovarian metastasis of gastric cancer. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1121-1138.	2.0	6
1267	Combined immunotherapy for metastatic triple-negative breast cancer based on PD-1/PD-L1 immune checkpoint blocking. <i>International Immunopharmacology</i> , 2022, 113, 109444.	1.7	6
1268	Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation. <i>British Journal of Cancer</i> , 2023, 128, 266-274.	2.9	2
1269	Disruption of RBMS3 suppresses PD-L1 and enhances antitumor immune activities and therapeutic effects of auranofin against triple-negative breast cancer. <i>Chemico-Biological Interactions</i> , 2023, 369, 110260.	1.7	8
1272	Emerging nano-strategies against tumour microenvironment (TME): a review. <i>OpenNano</i> , 2023, 9, 100112.	1.8	5
1273	The prognostic impact of tumor-infiltrating B lymphocytes in patients with solid malignancies: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 181, 103893.	2.0	1
1274	Biomedical applications and prospects of temperature-orchestrated photothermal therapy. , 2022, 1, .		5

#	ARTICLE	IF	CITATIONS
1275	Identification of molecular classification and gene signature for predicting prognosis and immunotherapy response in HNSCC using cell differentiation trajectories. <i>Scientific Reports</i> , 2022, 12, .	1.6	6
1276	The Combination of Inflammatory Biomarkers as Prognostic Indicator in Salivary Gland Malignancy. <i>Cancers</i> , 2022, 14, 5934.	1.7	9
1277	Tumor-infiltrating immune cell status predicts successful response to immune checkpoint inhibitors in renal cell carcinoma. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
1278	Metabolism in Cancer Stem Cells: Targets for Clinical Treatment. <i>Cells</i> , 2022, 11, 3790.	1.8	5
1279	A 5-Pathway Signature Predicts Prognosis Based on Immune-Derived lncRNAs in Patients with Breast Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-17.	0.6	1
1280	Pan-cancer analyses reveal molecular and clinical characteristics of cuproptosis regulators. , 2023, 2, .		17
1281	Use of Novel m6A Regulator-mediated Methylation Modification Patterns in Distinct Tumor Microenvironment Profiles to Identify and Predict Glioma Prognosis and Progression, T-cell Dysfunction, and Clinical Response to ICI Immunotherapy. <i>Current Pharmaceutical Design</i> , 2023, 29, 60-78.	0.9	1
1282	Radiotherapy Induces Innate Immune Responses in Patients Treated for Prostate Cancers. <i>Clinical Cancer Research</i> , 2023, 29, 921-929.	3.2	2
1283	Characterization of the tumor-infiltrating lymphocyte landscape in sinonasal mucosal melanoma. <i>Pathology Research and Practice</i> , 2022, , 154289.	1.0	0
1284	m6A regulators featured by tumor immune microenvironment landscapes and correlated with immunotherapy in non-small cell lung cancer (NSCLC). <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1285	Intratumoral immune heterogeneity of prostate cancer characterized by typing and hub genes. <i>Journal of Cellular and Molecular Medicine</i> , 2023, 27, 101-112.	1.6	2
1286	Integrated molecular analyses of an interferon- γ based subtype with regard to outcome, immune characteristics, and immunotherapy in bladder cancer and experimental verification. <i>Heliyon</i> , 2022, 8, e12102.	1.4	0
1287	DC vaccines loaded with glioma cells killed by photodynamic therapy induce Th17 anti-tumor immunity and provide a four-gene signature for glioma prognosis. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	10
1288	Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment. <i>Expert Opinion on Therapeutic Targets</i> , 2022, 26, 923-936.	1.5	6
1289	Dexmedetomidine provides type-specific tumour suppression without tumour-enhancing effects in syngeneic murine models. <i>British Journal of Anaesthesia</i> , 2023, 130, 142-153.	1.5	4
1290	High-throughput in situ perturbation of metabolite levels in the tumor micro-environment reveals favorable metabolic condition for increased fitness of infiltrated T-cells. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	1
1291	Intra-Tumoral Secondary Follicle-like Tertiary Lymphoid Structures Are Associated with a Superior Prognosis of Overall Survival of Perihilar Cholangiocarcinoma. <i>Cancers</i> , 2022, 14, 6107.	1.7	6
1292	Design of Nanoparticles in Cancer Therapy Based on Tumor Microenvironment Properties. <i>Pharmaceutics</i> , 2022, 14, 2708.	2.0	1

#	ARTICLE	IF	CITATIONS
1293	Therapeutic Targeting of DNA Damage Repair in the Era of Precision Oncology and Immune Checkpoint Inhibitors. <i>Journal of Immunotherapy and Precision Oncology</i> , 2023, 6, 31-49.	0.6	1
1294	Identification and validation of a ferroptosis-related lncRNA signature to robustly predict the prognosis, immune microenvironment, and immunotherapy efficiency in patients with clear cell renal cell carcinoma. <i>PeerJ</i> , 0, 10, e14506.	0.9	10
1295	BAP1 and PTEN mutations shape the immunological landscape of clear cell renal cell carcinoma and reveal the intertumoral heterogeneity of T cell suppression: a proof-of-concept study. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1603-1618.	2.0	6
1296	Identification of a Novel Myc-Regulated Gene Signature for Patients with Kidney Renal Clear Cell Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-21.	0.6	1
1297	Establishing a signature based on immunogenic cell death-related gene pairs to predict immunotherapy and survival outcomes of patients with hepatocellular carcinoma. <i>Aging</i> , 0, .	1.4	2
1298	Tertiary lymphoid structures are critical for cancer prognosis and therapeutic response. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
1299	Identifying Immune-Specific Subtypes of Adrenocortical Carcinoma Based on Immunogenomic Profiling. <i>Biomolecules</i> , 2023, 13, 104.	1.8	2
1300	Cross-talk between cuproptosis and ferroptosis regulators defines the tumor microenvironment for the prediction of prognosis and therapies in lung adenocarcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	20
1301	Vasoactive intestinal peptide blockade suppresses tumor growth by regulating macrophage polarization and function in CT26 tumor-bearing mice. <i>Scientific Reports</i> , 2023, 13, .	1.6	5
1302	Immune microenvironment infiltration landscape and immune-related subtypes in prostate cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
1303	Editorial: Impact of tumor microenvironment on lung cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
1305	Identification and Analysis of Potential Immune-Related Biomarkers in Endometriosis. <i>Journal of Immunology Research</i> , 2023, 2023, 1-21.	0.9	7
1306	The other immuno-PET: Metabolic tracers in evaluation of immune responses to immune checkpoint inhibitor therapy for solid tumors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
1307	<i>LINC00669</i> promotes lung adenocarcinoma growth by stimulating the Wnt/ β -catenin signaling pathway. <i>Cancer Medicine</i> , 0, .	1.3	2
1308	Hepatitis E Virus Seroprevalence Indicated a Significantly Increased Risk Selectively in Patients with Gastric Cancer among 17 Common Malignancies. <i>Journal of Clinical Medicine</i> , 2023, 12, 437.	1.0	2
1309	Guidelines for visualization and analysis of DC in tissues using multiparameter fluorescence microscopy imaging methods. <i>European Journal of Immunology</i> , 2023, 53, .	1.6	9
1310	Comprehensive analysis of the prognosis and immune infiltrates for the BET protein family reveals the significance of BRD4 in glioblastoma multiforme. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	1.8	2
1312	Myeloid-derived suppressor cells in head and neck squamous cell carcinoma. <i>International Review of Cell and Molecular Biology</i> , 2023, , 33-92.	1.6	2

#	ARTICLE	IF	CITATIONS
1313	Coupling the immunomodulatory properties of the HDAC6 inhibitor ACY241 with Oxaliplatin promotes robust anti-tumor response in Non-small cell lung cancer. <i>Journal of Immunology</i> , 2022, 208, 118.11-118.11.	0.4	2
1314	Advancements in Cancer Immunotherapies. <i>Vaccines</i> , 2023, 11, 59.	2.1	8
1315	The Cytokine Network in Colorectal Cancer: Implications for New Treatment Strategies. <i>Cells</i> , 2023, 12, 138.	1.8	15
1316	miR-29c Suppresses the Malignant Phenotype of Hepatocellular Carcinoma Cells In Vitro by Mediating TPX2 Associated with Immune Infiltration. <i>Digestive Diseases and Sciences</i> , 0, , .	1.1	0
1317	The PTEN-associated immune prognostic signature reveals the landscape of the tumor microenvironment in glioblastoma. <i>Journal of Neuroimmunology</i> , 2023, 376, 578034.	1.1	1
1319	A flexible liposomal polymer complex as a platform of specific and regulable immune regulation for individual cancer immunotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, .	3.5	0
1321	Autoimmune diseases as comorbidities for liver, gallbladder, and biliary duct cancers in Sweden. <i>Cancer</i> , 0, , .	2.0	0
1322	ImmunPET Imaging of Immune Checkpoints to Assess Their Cancer Therapeutic Potential. , 2023, , 1-34.		0
1323	The prognostic value and immune correlation of IL18 expression and promoter methylation in renal cell carcinoma. <i>Clinical Epigenetics</i> , 2023, 15, .	1.8	3
1324	Bodywide ecological interventions on cancer. <i>Nature Medicine</i> , 2023, 29, 59-74.	15.2	17
1325	The immune microenvironment in somatotropinomas: from biology to personalized and target therapy. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2023, 24, 283-295.	2.6	6
1326	A signature-based classification of lung adenocarcinoma that stratifies tumor immunity. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1327	Reversing the NK inhibitory tumor microenvironment by targeting suppressive immune effectors. , 2023, , 27-63.		1
1328	Single-cell transcriptome analysis reveals functional changes in tumour-infiltrating B lymphocytes after chemotherapy in oesophageal squamous cell carcinoma. <i>Clinical and Translational Medicine</i> , 2023, 13, .	1.7	1
1329	Identification of prognostic immune-related lncRNA signature predicting the overall survival for colorectal cancer. <i>Scientific Reports</i> , 2023, 13, .	1.6	3
1330	Genomic and immune landscape Of metastatic pheochromocytoma and paraganglioma. <i>Nature Communications</i> , 2023, 14, .	5.8	8
1331	Localization and density of tertiary lymphoid structures associate with molecular subtype and clinical outcome in colorectal cancer liver metastases. , 2023, 11, e006425.		12
1333	Characterization of expression and prognostic implications of transforming growth factor beta, programmed death-ligand 1, and T regulatory cells in canine histiocytic sarcoma. <i>Veterinary Immunology and Immunopathology</i> , 2023, 257, 110560.	0.5	0

#	ARTICLE	IF	CITATIONS
1334	Heterogeneity of Cholangiocarcinoma Immune Biology. <i>Cells</i> , 2023, 12, 846.	1.8	5
1335	Adaptive Immunity in Genitourinary Cancers. <i>European Urology Oncology</i> , 2023, 6, 263-272.	2.6	3
1336	Second near-infrared light-activated semiconducting polymer nanomediators enable three-in-one tumor microenvironment modulation for combination immunotherapy. <i>Nano Today</i> , 2023, 50, 101833.	6.2	9
1337	Syndecan-1 as an immunogene in Triple-negative breast cancer: regulation tumor-infiltrating lymphocyte in the tumor microenvironment and EMT by TGFb1/Smad pathway. <i>Cancer Cell International</i> , 2023, 23, .	1.8	0
1339	CXCR3 Expression Is Associated with Advanced Tumor Stage and Grade Influencing Survival after Surgery of Localised Renal Cell Carcinoma. <i>Cancers</i> , 2023, 15, 1001.	1.7	1
1340	Alterations in Natural Killer Cells in Colorectal Cancer Patients with Stroma AReactive Invasion Front Areas (SARIFA). <i>Cancers</i> , 2023, 15, 994.	1.7	7
1341	The immune-metabolic crosstalk between CD3+C1q+TAM and CD8+T cells associated with relapse-free survival in HCC. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
1342	Tertiary Lymphoid Structures Are Associated with a Favorable Prognosis in High-Grade Serous Ovarian Cancer Patients. <i>Reproductive Sciences</i> , 0, , .	1.1	1
1344	Prognostic and immunological role of alpha-L-fucosidase 2 (FUCA2) in hepatocellular carcinoma. <i>Translational Cancer Research</i> , 2023, 12, 257-272.	0.4	1
1346	Promises and challenges for targeting the immunological players in the tumor micro-environment â€œ Critical determinants for NP-based therapy. <i>OpenNano</i> , 2023, 10, 100134.	1.8	1
1347	Establishment of a risk score model for bladder urothelial carcinoma based on energy metabolismâ€™related genes and their relationships with immune infiltration. <i>FEBS Open Bio</i> , 2023, 13, 736-750.	1.0	2
1348	Metabolic classifications of renal cell carcinoma reveal intrinsic connections with clinical and immune characteristics. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	2
1349	Development of in vitro laboratory models of the tumor immune microenvironment to evaluate quality parameters and specific efficacy of the dendritic cell vaccine. <i>Siberian Journal of Oncology</i> , 2023, 22, 82-94.	0.1	0
1350	A cuproptosis-related LncRNA signature: Integrated analysis associated with biochemical recurrence and immune landscape in prostate cancer. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	0
1351	Mechanisms of Immunological Toxicity in Cancer Immunotherapy with Checkpoint Inhibitors. , 2023, , 1-18.		0
1352	Immunogenic cell death in cancer: concept and therapeutic implications. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	26
1353	A Comprehensive Analysis of Programmed Cell Death-Associated Genes for Tumor Microenvironment Evaluation Promotes Precise Immunotherapy in Patients with Lung Adenocarcinoma. <i>Journal of Personalized Medicine</i> , 2023, 13, 476.	1.1	0
1354	Clinical implications and molecular features of tertiary lymphoid structures in stage I lung adenocarcinoma. <i>Cancer Medicine</i> , 2023, 12, 9547-9558.	1.3	2

#	ARTICLE	IF	CITATIONS
1355	Significance of CD80 as a Prognostic and Immunotherapeutic Biomarker in Lung Adenocarcinoma. <i>Biochemical Genetics</i> , 2023, 61, 1937-1966.	0.8	1
1356	Neutrophil-to-lymphocyte ratio as an independent factor for worse prognosis in radioiodine refractory thyroid cancer patients. <i>Endocrine</i> , 0, .	1.1	0
1357	Integrative analysis revealed that distinct cuprotosis patterns reshaped tumor microenvironment and responses to immunotherapy of colorectal cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
1358	An integrated analysis of Dynamin 1 Like: A new potential prognostic indicator in hepatocellular carcinoma. <i>Molecular Carcinogenesis</i> , 2023, 62, 786-802.	1.3	2
1359	Immune microenvironment of medulloblastoma: The association between its molecular subgroups and potential targeted immunotherapeutic receptors. <i>World Journal of Clinical Oncology</i> , 0, 14, 117-130.	0.9	1
1361	Vascular Normalization Was Associated with Colorectal Tumor Regression upon Anti-PD-L1 Combinational Therapy. <i>Journal of Immunology Research</i> , 2023, 2023, 1-13.	0.9	2
1362	Editorial: Profiling the tumour microenvironment to unveil biomarkers and develop novel therapeutics for cancer therapy. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	0
1363	CD25 ^{bright} NK cells display superior function and metabolic activity under regulatory T cell-mediated suppression. <i>Oncolmmunology</i> , 2023, 12, .	2.1	1
1364	Activatable near-infrared probes for the detection of specific populations of tumour-infiltrating leukocytes in vivo and in urine. <i>Nature Biomedical Engineering</i> , 2023, 7, 281-297.	11.6	28
1366	Prognostic impact of CD73/adenosine 2A receptor (A2AR) in renal cell carcinoma and immune microenvironmental status with sarcomatoid changes and rhabdoid features. <i>Pathology Research and Practice</i> , 2023, 244, 154423.	1.0	1
1367	<scp>CD68</scp>+ and <scp>CD8</scp>+ immune cells are associated with the growth pattern of somatotroph tumors and response to first generation somatostatin analogs. <i>Journal of Neuroendocrinology</i> , 2023, 35, .	1.2	6
1368	Precision Medicine in the Treatment of Malignancies Involving the Ventral Skull Base: Present and Future. , 2023, , 237-291.		0
1369	LRP1B mutation is associated with tumor immune microenvironment and progression-free survival in lung adenocarcinoma treated with immune checkpoint inhibitors. <i>Translational Lung Cancer Research</i> , 2023, 12, 510-529.	1.3	2
1370	Expression Patterns of HOX Gene Family Defines Tumor Microenvironment and Immunotherapy in Hepatocellular Carcinoma. <i>Applied Biochemistry and Biotechnology</i> , 0, , .	1.4	0
1371	An immune indicator based on BTK and DPEP2 identifies hot and cold tumors and clinical treatment outcomes in lung adenocarcinoma. <i>Scientific Reports</i> , 2023, 13, .	1.6	2
1372	Development and validation of a novel defined mutation classifier based on Lasso logistic regression for predicting the overall survival of immune checkpoint inhibitor therapy in renal cell carcinoma. <i>Translational Andrology and Urology</i> , 2023, 12, 406-424.	0.6	0
1373	PIK3C2A is a prognostic biomarker that is linked to immune infiltrates in kidney renal clear cell carcinoma. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
1374	Exploring a ferroptosis and oxidative stress-based prognostic model for clear cell renal cell carcinoma. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1

#	ARTICLE	IF	CITATIONS
1375	Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	14
1376	Targeting the Molecular and Immunologic Features of Leiomyosarcoma. <i>Cancers</i> , 2023, 15, 2099.	1.7	5
1377	Spatially resolved multimarker evaluation of CD274 (PD-L1)/PDCD1 (PD-1) immune checkpoint expression and macrophage polarisation in colorectal cancer. <i>British Journal of Cancer</i> , 2023, 128, 2104-2115.	2.9	10
1379	Regulatory Mechanisms and Reversal of CD8+T Cell Exhaustion: A Literature Review. <i>Biology</i> , 2023, 12, 541.	1.3	2
1380	Density and maturity of peritumoral tertiary lymphoid structures in oesophageal squamous cell carcinoma predicts patient survival and response to immune checkpoint inhibitors. <i>British Journal of Cancer</i> , 2023, 128, 2175-2185.	2.9	9
1381	Molecular subtypes, tumor microenvironment infiltration characterization and prognosis model based on cuproptosis in bladder cancer. <i>PeerJ</i> , 0, 11, e15088.	0.9	0
1383	A prognostic and immunotherapeutic predictive model based on the cell-originated characterization of tumor microenvironment in lung adenocarcinoma. <i>IScience</i> , 2023, 26, 106616.	1.9	0
1384	Targeting B7-H3â€”A Novel Strategy for the Design of Anticancer Agents for Extracranial Pediatric Solid Tumors Treatment. <i>Molecules</i> , 2023, 28, 3356.	1.7	4
1385	Macrophage morphology and distribution are strong predictors of prognosis in resected colorectal liver metastases: results from an external retrospective observational study. <i>International Journal of Surgery</i> , 2023, 109, 1311-1317.	1.1	2
1386	Identification of immune cell infiltration landscape for predicting prognosis of colorectal cancer. <i>Gastroenterology Report</i> , 2022, 11, .	0.6	3
1388	Discussion Ã propos de la communicationÃ: Â«ÃBiomarqueurs prÃ©dictifs de la rÃ©ponse Ã lâ€™immunothÃ©rapie dans les mÃ©lanomesÃ». <i>Bulletin De L'Academie Nationale De Medecine</i> , 2023, 207, 829-831.	0.0	0
1389	Deciphering the maturation of tertiary lymphoid structures in cancer and inflammatory diseases of the digestive tract using imaging mass cytometry. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
1390	Intratumoral tertiary lymphoid structure (TLS) maturation is influenced by draining lymph nodes of lung cancer. , 2023, 11, e005539.		7
1391	Innate lymphoid cells and innate-like T cells in cancerâ€” at the crossroads of innate and adaptive immunity. <i>Nature Reviews Cancer</i> , 2023, 23, 351-371.	12.8	15
1392	Cancer Surveillance. , 2023, , 271-341.		0
1393	Information about immune cell proportions and tumor stage improves the prediction of recurrence in patients with colorectal cancer. <i>Patterns</i> , 2023, , 100736.	3.1	0
1394	The Cancer Driver Genes IDH1 and IDH2 and CD204 in WHO-Grade 4 Astrocytoma: Crosstalk Between Cancer Metabolism and Tumour Associated Macrophage Recruitment in Tumour Microenvironment. <i>Biologics: Targets and Therapy</i> , 0, Volume 17, 15-22.	3.0	1
1423	Next-generation deconvolution of transcriptomic data to investigate the tumor microenvironment. <i>International Review of Cell and Molecular Biology</i> , 2024, , 103-143.	1.6	1

#	ARTICLE	IF	CITATIONS
1426	The role of IL-1 in tumor growth and angiogenesis. , 2023, , 71-86.		0
1442	Quantitative multiplexed imaging technologies for single-cell analysis to assess predictive markers for immunotherapy in thoracic immuno-oncology: promises and challenges. British Journal of Cancer, 2023, 129, 1417-1431.	2.9	5
1451	Local Onco-Sphere: Tumor-Immune Cells Interactions. , 2023, , 51-76.		0
1480	è,žç,ã...³çš,,ä,%oç°\$æ·â·ç»“æž,,çš,,æ£€æµ«â'ŒéþâŒ-â†æž, Journal of Zhejiang University: Science B, 2023, 24, 739-795. 1		
1488	The cancer-immune dialogue in the context of stress. Nature Reviews Immunology, 0, , .	10.6	6
1518	An Updated Review on KRAS Mutation in Lung Cancer (NSCLC) and Its Effects on Human Health. Applied Biochemistry and Biotechnology, 0, , .	1.4	0
1566	Milestones in cancer research. , 2024, , 1-13.		0
1584	Proteomics: Unraveling the Cross Talk Between Innate Immunity and Disease Pathophysiology, Diagnostics, and Treatment Options. Advances in Experimental Medicine and Biology, 2024, , 221-242.	0.8	0